Transcription	B-protein
factor	I-protein
B-cell-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
is	O
differentially	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
in	O
subsets	O
of	O
B-cell	O
lymphomas	O
.	O

The	O
paired	B-DNA
box	I-DNA
containing	I-DNA
gene	I-DNA
PAX-5	B-DNA
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
(	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
B-lymphocyte	O
development	O
.	O

Despite	O
its	O
known	O
involvement	O
in	O
a	O
rare	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
a	O
detailed	O
examination	O
of	O
BSAP	B-protein
expression	O
in	O
NHL	O
has	O
not	O
been	O
previously	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
normal	O
and	O
malignant	O
lymphoid	O
tissues	O
and	O
cell	B-cell_line
lines	I-cell_line
,	O
including	O
102	O
cases	O
of	O
B-cell	O
NHL	O
,	O
23	O
cases	O
of	O
T-	O
and	O
null-cell	O
NHL	O
,	O
and	O
18	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
.	O

Normal	O
lymphoid	O
tissues	O
showed	O
strong	O
nuclear	O
BSAP	B-protein
expression	O
in	O
mantle	B-cell_type
zone	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
less	O
intense	O
reactivity	O
in	O
follicular	B-cell_type
center	I-cell_type
B	I-cell_type
cells	I-cell_type
,	O
and	O
no	O
expression	O
in	O
cells	O
of	O
the	O
T-cell-rich	O
zones	O
.	O

Monocytoid	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
weak	O
expression	O
,	O
whereas	O
plasma	B-cell_type
cells	I-cell_type
and	O
extrafollicular	B-cell_type
large	I-cell_type
transformed	I-cell_type
B	I-cell_type
cells	I-cell_type
were	O
negative	O
.	O

Of	O
the	O
102	O
B-cell	O
NHLs	O
,	O
83	O
(	O
81	O
%	O
)	O
demonstrated	O
BSAP	B-protein
expression	O
.	O

All	O
of	O
the	O
13	O
(	O
100	O
%	O
)	O
B-cell	O
chronic	O
lymphocytic	O
leukemias	O
(	O
B-CLLs	O
)	O
,	O
21	O
of	O
(	O
100	O
%	O
)	O
mantle	B-cell_type
cells	I-cell_type
(	O
MCLs	B-cell_type
)	O
,	O
and	O
20	O
of	O
21	O
(	O
95	O
%	O
)	O
follicular	O
lymphomas	O
(	O
FLs	O
)	O
were	O
positive	O
.	O

Moderate	O
staining	O
intensities	O
were	O
found	O
in	O
most	O
B-CLL	O
and	O
FL	O
cases	O
,	O
whereas	O
most	O
MCLs	B-cell_type
showed	O
strong	O
reactions	O
,	O
paralleling	O
the	O
strong	O
reactivity	O
of	O
nonmalignant	B-cell_type
mantle	I-cell_type
cells	I-cell_type
.	O

Eight	O
of	O
12	O
(	O
67	O
%	O
)	O
marginal	O
zone	O
lymphoma	O
cases	O
showed	O
negative	O
or	O
low	O
BSAP	B-protein
levels	O
,	O
and	O
17	O
of	O
24	O
(	O
71	O
%	O
)	O
large	O
B-cell	O
lymphomas	O
displayed	O
moderate	O
to	O
strong	O
expression	O
.	O

None	O
of	O
the	O
23	O
T-	O
and	O
null-cell	O
lymphomas	O
reacted	O
with	O
the	O
BSAP	B-protein
antisera	O
,	O
whereas	O
in	O
Hodgkin	O
's	O
disease	O
,	O
2	O
of	O
4	O
(	O
50	O
%	O
)	O
nodular	O
lymphocytic	O
predominance	O
and	O
5	O
of	O
14	O
(	O
36	O
%	O
)	O
classical	O
cases	O
showed	O
weak	O
nuclear	O
or	O
nucleolar	O
BSAP	B-protein
reactions	O
in	O
a	O
fraction	O
of	O
the	O
tumor	B-cell_type
cells	I-cell_type
.	O

Western	O
blot	O
analysis	O
showed	O
a	O
52-kD	O
BSAP	B-protein
band	O
in	O
B-cell	B-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
non-B-cell	B-cell_line
or	I-cell_line
plasma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
conclude	O
that	O
BSAP	B-protein
expression	O
is	O
largely	O
restricted	O
to	O
lymphomas	O
of	O
B-cell	B-cell_type
lineage	I-cell_type
and	O
that	O
BSAP	B-protein
expression	O
varies	O
in	O
B-cell	B-cell_type
subsets	I-cell_type
and	O
subtypes	O
of	O
B-cell	O
NHL	O
.	O

The	O
high	O
levels	O
of	O
BSAP	B-protein
,	O
especially	O
those	O
found	O
in	O
large-cell	B-cell_type
lymphomas	I-cell_type
and	O
in	O
some	O
follicular	B-cell_type
lymphomas	I-cell_type
,	O
may	O
be	O
a	O
consequence	O
of	O
deregulated	O
gene	O
expression	O
and	O
suggest	O
a	O
possible	O
involvement	O
of	O
PAX-5	B-DNA
in	O
certain	O
B-cell	O
malignancies	O
.	O

This	O
is	O
a	O
US	O
government	O
work	O
.	O

There	O
are	O
no	O
restrictions	O
on	O
its	O
use	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Transcription	NULL
Factor	NULL
B-Cell-Specific	NULL
Activator	NULL
Protein	NULL
(	NULL
BSAP	NULL
)	NULL
Is	NULL
Differentially	NULL
Expressed	NULL
in	NULL
B	NULL
Cells	NULL
and	NULL
in	NULL
Subsets	NULL
of	NULL
B-Cell	NULL
Lymphomas	NULL
By	NULL
Laszlo	NULL
Krenacs	NULL
,	NULL
Andreas	NULL
W.	NULL
Himmelmann	NULL
,	NULL
Leticia	NULL
Quintanilla-Martinez	NULL
,	NULL
Thierry	NULL
Fest	NULL
,	NULL
Agostino	NULL
Riva	NULL
,	NULL
Axel	NULL
Wellmann	NULL
,	NULL
Eniko	NULL
Bagdi	NULL
,	NULL
John	NULL
H.	NULL
Kehrl	NULL
,	NULL
Elaine	NULL
S.	NULL
Jaffe	NULL
,	NULL
and	NULL
Mark	NULL
Raffeld	NULL
The	NULL
paired	NULL
box	NULL
containing	NULL
gene	NULL
PAX-5	NULL
encodes	NULL
the	NULL
transcription	NULL
factor	NULL
BSAP	NULL
(	NULL
B-cell-specific	NULL
activator	NULL
protein	NULL
)	NULL
,	NULL
which	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
B-lymphocyte	NULL
development	NULL
.	NULL

Despite	NULL
its	NULL
known	NULL
involvement	NULL
in	NULL
a	NULL
rare	NULL
subtype	NULL
of	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
(	NULL
NHL	NULL
)	NULL
,	NULL
a	NULL
detailed	NULL
examination	NULL
of	NULL
BSAP	NULL
expression	NULL
in	NULL
NHL	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
reported	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
analyzed	NULL
normal	NULL
and	NULL
malignant	NULL
lymphoid	NULL
tissues	NULL
and	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
102	NULL
cases	NULL
of	NULL
B-cell	NULL
NHL	NULL
,	NULL
23	NULL
cases	NULL
of	NULL
T-	NULL
and	NULL
null-cell	NULL
NHL	NULL
,	NULL
and	NULL
18	NULL
cases	NULL
of	NULL
Hodgkin	NULL
's	NULL
disease	NULL
.	NULL

Normal	NULL
lymphoid	NULL
tissues	NULL
showed	NULL
strong	NULL
nuclear	NULL
BSAP	NULL
expression	NULL
in	NULL
mantle	NULL
zone	NULL
B	NULL
cells	NULL
,	NULL
less	NULL
intense	NULL
reactivity	NULL
in	NULL
follicular	NULL
center	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
no	NULL
expression	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
T-cell-rich	NULL
zones	NULL
.	NULL

Monocytoid	NULL
B	NULL
cells	NULL
showed	NULL
weak	NULL
expression	NULL
,	NULL
whereas	NULL
plasma	NULL
cells	NULL
and	NULL
extrafollicular	NULL
large	NULL
transformed	NULL
B	NULL
cells	NULL
were	NULL
negative	NULL
.	NULL

Of	NULL
the	NULL
102	NULL
B-cell	NULL
NHLs	NULL
,	NULL
83	NULL
(	NULL
81	NULL
%	NULL
)	NULL
demonstrated	NULL
BSAP	NULL
expression	NULL
.	NULL

All	NULL
of	NULL
the	NULL
13	NULL
(	NULL
100	NULL
%	NULL
)	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemias	NULL
(	NULL
B-CLLs	NULL
)	NULL
,	NULL
21	NULL
of	NULL
(	NULL
100	NULL
%	NULL
)	NULL
mantle	NULL
cells	NULL
(	NULL
MCLs	NULL
)	NULL
,	NULL
and	NULL
20	NULL
of	NULL
21	NULL
(	NULL
95	NULL
%	NULL
)	NULL
follicular	NULL
lymphomas	NULL
(	NULL
FLs	NULL
)	NULL
were	NULL
positive	NULL
.	NULL

Moderate	NULL
staining	NULL
intensities	NULL
were	NULL
found	NULL
in	NULL
most	NULL
B-CLL	NULL
and	NULL
FL	NULL
cases	NULL
,	NULL
whereas	NULL
most	NULL
MCLs	NULL
showed	NULL
strong	NULL
B-CELL—SPECIFIC	NULL
activator	NULL
protein	NULL
(	NULL
BSAP	NULL
)	NULL
is	NULL
a	NULL
52-kD	NULL
transcription	NULL
factor	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
mammalian	NULL
homologue	NULL
of	NULL
the	NULL
sea	NULL
urchin	NULL
tissue-specific	NULL
activator	NULL
protein	NULL
(	NULL
TSAP	NULL
)	NULL
.	NULL

!	NULL

BSAP	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
Pax-5	NULL
gene	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
highly	NULL
conserved	NULL
paired	NULL
box	NULL
(	NULL
Pax	NULL
)	NULL
gene	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
``	NULL
and	NULL
is	NULL
equivalent	NULL
to	NULL
the	NULL
NF-HB	NULL
,	NULL
``	NULL
Sa-BP	NULL
,	NULL
A	NULL
NFSp-B1	NULL
,	NULL
``	NULL
LR1	NULL
,	NULL
°	NULL
and	NULL
EBB-1	NULL
``	NULL
B-cell	NULL
specific	NULL
nuclear	NULL
factors	NULL
identified	NULL
by	NULL
different	NULL
investigators	NULL
.	NULL
``	NULL

Among	NULL
hematopoietic	NULL
cells	NULL
,	NULL
Pax-5	NULL
gene	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
B-cell	NULL
lineage	NULL
.	NULL
``	NULL

Pax-5	NULL
gene	NULL
transcription	NULL
is	NULL
initiated	NULL
in	NULL
pro-B	NULL
cells	NULL
and	NULL
is	NULL
abundant	NULL
at	NULL
the	NULL
pre-B-	NULL
and	NULL
mature	NULL
B-cell	NULL
differentiation	NULL
stages	NULL
,	NULL
but	NULL
absent	NULL
in	NULL
terminally	NULL
differentiated	NULL
plasma	NULL
cells	NULL
.	NULL

Pax-5	NULL
gene	NULL
expression	NULL
also	NULL
occurs	NULL
in	NULL
the	NULL
mesencephalon	NULL
and	NULL
spinal	NULL
cord	NULL
during	NULL
embryogenesis	NULL
and	NULL
in	NULL
the	NULL
adult	NULL
testis	NULL
.	NULL
``	NULL

BSAP	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
several	NULL
B-cell-specific	NULL
genes	NULL
,	NULL
in	NULL
controlling	NULL
B-cell	NULL
development	NULL
,	NULL
and	NULL
in	NULL
From	NULL
the	NULL
Hematopathology	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Pathology	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
and	NULL
the	NULL
B	NULL
cell	NULL
Molecular	NULL
Immunology	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Immunoregulation	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
;	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Albert	NULL
Szent-Gyorgyi	NULL
Medical	NULL
University	NULL
,	NULL
Szeged	NULL
,	NULL
Hungary	NULL
.	NULL

Submitted	NULL
October	NULL
20	NULL
,	NULL
1997	NULL
;	NULL
accepted	NULL
April	NULL
8	NULL
,	NULL
1998	NULL
.	NULL

LK	NULL
.	NULL

and	NULL
A.W.H	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
study	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Swiss	NULL
National	NULL
Foundation	NULL
to	NULL
AWH	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Mark	NULL
Raffeld	NULL
,	NULL
MD	NULL
,	NULL
Hematopathology	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Pathology	NULL
,	NULL
Bldg	NULL
10	NULL
,	NULL
Room	NULL
2N110	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
9000	NULL
Rockville	NULL
Pike	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

This	NULL
is	NULL
a	NULL
US	NULL
government	NULL
work	NULL
.	NULL

There	NULL
are	NULL
no	NULL
restrictions	NULL
on	NULL
its	NULL
use	NULL
.	NULL

0006-4971/98/9204-0034	NULL
$	NULL
0.00/0	NULL
1308	NULL
reactions	NULL
,	NULL
paralleling	NULL
the	NULL
strong	NULL
reactivity	NULL
of	NULL
nonmalignant	NULL
mantle	NULL
cells	NULL
.	NULL

Eight	NULL
of	NULL
12	NULL
(	NULL
67	NULL
%	NULL
)	NULL
marginal	NULL
zone	NULL
lymphoma	NULL
cases	NULL
showed	NULL
negative	NULL
or	NULL
low	NULL
BSAP	NULL
levels	NULL
,	NULL
and	NULL
17	NULL
of	NULL
24	NULL
(	NULL
71	NULL
%	NULL
)	NULL
large	NULL
B-cell	NULL
lymphomas	NULL
displayed	NULL
moderate	NULL
to	NULL
strong	NULL
expression	NULL
.	NULL

None	NULL
of	NULL
the	NULL
23	NULL
T-	NULL
and	NULL
null-cell	NULL
lymphomas	NULL
reacted	NULL
with	NULL
the	NULL
BSAP	NULL
antisera	NULL
,	NULL
whereas	NULL
in	NULL
Hodgkin	NULL
's	NULL
dis-ease	NULL
,	NULL
2	NULL
of	NULL
4	NULL
(	NULL
50	NULL
%	NULL
)	NULL
nodular	NULL
lymphocytic	NULL
predominance	NULL
and	NULL
5	NULL
of	NULL
14	NULL
(	NULL
36	NULL
%	NULL
)	NULL
classical	NULL
cases	NULL
showed	NULL
weak	NULL
nuclear	NULL
or	NULL
nucleolar	NULL
BSAP	NULL
reactions	NULL
in	NULL
a	NULL
fraction	NULL
of	NULL
the	NULL
tumor	NULL
cells	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
show	NULL
ed	NULL
a	NULL
52-kD	NULL
BSAP	NULL
band	NULL
in	NULL
B-cell	NULL
lines	NULL
,	NULL
but	NULL
not	NULL
in	NULL
non-B-cell	NULL
or	NULL
plasma	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
BSAP	NULL
expression	NULL
is	NULL
largely	NULL
restricted	NULL
to	NULL
lymphomas	NULL
of	NULL
B-cell	NULL
lineage	NULL
and	NULL
that	NULL
BSAP	NULL
expression	NULL
varies	NULL
in	NULL
B-cell	NULL
subsets	NULL
and	NULL
subtypes	NULL
of	NULL
B-cell	NULL
NHL	NULL
.	NULL

The	NULL
high	NULL
levels	NULL
of	NULL
BSAP	NULL
,	NULL
especially	NULL
those	NULL
found	NULL
in	NULL
large-cell	NULL
|ymphomas	NULL
and	NULL
in	NULL
some	NULL
follicular	NULL
lymphomas	NULL
,	NULL
may	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
deregulated	NULL
gene	NULL
expression	NULL
and	NULL
suggest	NULL
a	NULL
possible	NULL
involvement	NULL
of	NULL
PAX-5	NULL
in	NULL
certain	NULL
B-cell	NULL
malignancies	NULL
.	NULL

This	NULL
is	NULL
a	NULL
US	NULL
government	NULL
work	NULL
.	NULL

There	NULL
are	NULL
no	NULL
restrictions	NULL
on	NULL
its	NULL
use	NULL
.	NULL

mediating	NULL
the	NULL
balance	NULL
between	NULL
B-cell	NULL
proliferation	NULL
and	NULL
Ig	NULL
BSAP	NULL
is	NULL
believed	NULL
to	NULL
be	NULL
a	NULL
key	NULL
protein	NULL
for	NULL
transcrip-tional	NULL
regulation	NULL
of	NULL
the	NULL
CD19	NULL
gene*	NULL
``	NULL
``	NULL
and	NULL
is	NULL
identical	NULL
to	NULL
EBB-1,8	NULL
a	NULL
factor	NULL
reported	NULL
to	NULL
regulate	NULL
transcription	NULL
of	NULL
the	NULL
surrogate	NULL
light	NULL
chain	NULL
genes	NULL
VpreB	NULL
and	NULL
A5	NULL
.	NULL
``	NULL

BSAP	NULL
binding	NULL
sites	NULL
are	NULL
found	NULL
upstream	NULL
of	NULL
and	NULL
within	NULL
Ig	NULL
switch	NULL
regions	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
BSAP	NULL
in	NULL
regulating	NULL
class	NULL
switching	NULL
.	NULL

**	NULL
``	NULL
``	NULL
``	NULL
The	NULL
functional	NULL
significance	NULL
of	NULL
a	NULL
BSAP	NULL
binding	NULL
site	NULL
located	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
remains	NULL
to	NULL
be	NULL
clarified	NULL
.	NULL

``	NULL
?	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
Pax-5	NULL
gene	NULL
in	NULL
mice	NULL
blocks	NULL
B-cell	NULL
development	NULL
at	NULL
the	NULL
pro-B-cell	NULL
stage	NULL
,	NULL
implicating	NULL
a	NULL
role	NULL
for	NULL
BSAP	NULL
in	NULL
the	NULL
control	NULL
of	NULL
B-cell	NULL
development	NULL
.	NULL
``	NULL

''	NULL
Recently	NULL
,	NULL
BSAP	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
mature	NULL
B-cell	NULL
proliferation	NULL
.	NULL
``	NULL

The	NULL
addition	NULL
of	NULL
Pax-5	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
splenic	NULL
B-cell	NULL
cultures	NULL
reduced	NULL
BSAP	NULL
levels	NULL
and	NULL
impaired	NULL
the	NULL
proliferative	NULL
response	NULL
to	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
stimulation	NULL
.	NULL

Conversely	NULL
,	NULL
transient	NULL
overexpression	NULL
of	NULL
BSAP	NULL
enhanced	NULL
the	NULL
LPS	NULL
response.89	NULL
!	NULL

4	NULL
BSAP	NULL
may	NULL
also	NULL
have	NULL
an	NULL
important	NULL
repressor	NULL
function	NULL
for	NULL
Ig	NULL
heavy	NULL
chain	NULL
expression	NULL
by	NULL
suppressing	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
3	NULL
'	NULL
a	NULL
heavy	NULL
chain	NULL
enhancer	NULL
.	NULL

>	NULL
*'*	NULL
``	NULL
5	NULL
Thus	NULL
,	NULL
the	NULL
downregulation	NULL
of	NULL
BSAP	NULL
that	NULL
occurs	NULL
in	NULL
plasma	NULL
cells	NULL
may	NULL
be	NULL
essential	NULL
for	NULL
the	NULL
high	NULL
rate	NULL
of	NULL
Ig	NULL
production	NULL
found	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

There	NULL
are	NULL
9	NULL
paired	NULL
box	NULL
genes	NULL
known	NULL
in	NULL
human	NULL
(	NULL
PAX-I-9	NULL
)	NULL
and	NULL
mouse	NULL
(	NULL
Pax-1-9	NULL
)	NULL
.	NULL

Each	NULL
encodes	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
uses	NULL
the	NULL
paired	NULL
box	NULL
domain	NULL
to	NULL
recognize	NULL
DNA	NULL
elements	NULL
in	NULL
their	NULL
target	NULL
genes	NULL
.	NULL

!	NULL
``	NULL

Mammalian	NULL
PAX	NULL
genes	NULL
are	NULL
transiently	NULL
expressed	NULL
in	NULL
various	NULL
organs	NULL
during	NULL
embryogenesis	NULL
and	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
organogenesis	NULL
.	NULL
``	NULL

Loss-of-function	NULL
mutations	NULL
of	NULL
some	NULL
PAX	NULL
genes	NULL
are	NULL
important	NULL
in	NULL
some	NULL
rare	NULL
congenital	NULL
human	NULL
diseases	NULL
,	NULL
``	NULL
and	NULL
by	NULL
several	NULL
criteria	NULL
,	NULL
paired	NULL
box	NULL
genes	NULL
are	NULL
nuclear	NULL
proto-oncogenes	NULL
.	NULL

First	NULL
,	NULL
the	NULL
overexpression	NULL
of	NULL
different	NULL
Pax	NULL
genes	NULL
in	NULL
mouse	NULL
fibroblasts	NULL
causes	NULL
their	NULL
malignant	NULL
transformation	NULL
as	NULL
these	NULL
cells	NULL
can	NULL
form	NULL
tumors	NULL
in	NULL
nude	NULL
mice	NULL
.	NULL
``	NULL

Second	NULL
,	NULL
alterations	NULL
in	NULL
PAX	NULL
genes	NULL
,	NULL
particularly	NULL
gain-of-function	NULL
mutations	NULL
and	NULL
overexpression	NULL
,	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
unrelated	NULL
human	NULL
malignancies	NULL
,	NULL
possibly	NULL
contributing	NULL
Blood	NULL
,	NULL
Vol	NULL
92	NULL
,	NULL
No	NULL
4	NULL
(	NULL
August	NULL
15	NULL
)	NULL
,	NULL
1998	NULL
:	NULL
pp	NULL
1308-1316	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BSAP	NULL
EXPRESSION	NULL
IN	NULL
LYMPHOID	NULL
MALIGNANCIES	NULL
to	NULL
tumorigenesis	NULL
in	NULL
these	NULL
cancers	NULL
.	NULL

``	NULL
``	NULL
>	NULL
``	NULL
Deregulated	NULL
PAX-5	NULL
gene	NULL
expression	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
human	NULL
medulloblastomas®	NULL
and	NULL
in	NULL
adult	NULL
astrocytic	NULL
neoplasms	NULL
.	NULL
``	NULL

In	NULL
the	NULL
latter	NULL
tumors	NULL
,	NULL
PAX-5	NULL
expression	NULL
levels	NULL
correlated	NULL
with	NULL
the	NULL
degree	NULL
of	NULL
malignancy	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
BSAP	NULL
(	NULL
PAX-5	NULL
)	NULL
,	NULL
PAX-2	NULL
,	NULL
and	NULL
PAX-8	NULL
proteins	NULL
are	NULL
capable	NULL
of	NULL
inhibiting	NULL
the	NULL
function	NULL
of	NULL
p53	NULL
in	NULL
vitro	NULL
,	NULL
suggesting	NULL
another	NULL
mechanism	NULL
by	NULL
which	NULL
these	NULL
genes	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
development	NULL
of	NULL
neoplasia	NULL
.	NULL
``	NULL

''	NULL
Most	NULL
recently	NULL
,	NULL
the	NULL
PAX-5	NULL
gene	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
a	NULL
rare	NULL
subset	NULL
of	NULL
lymphoma	NULL
with	NULL
plasmacytic	NULL
differentiation	NULL
through	NULL
translocation	NULL
with	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
gene	NULL
locus	NULL
.	NULL
``	NULL

The	NULL
above-mentioned	NULL
data	NULL
and	NULL
the	NULL
proposed	NULL
key	NULL
role	NULL
of	NULL
BSAP	NULL
in	NULL
B-cell	NULL
differentiation	NULL
and	NULL
proliferation	NULL
suggest	NULL
that	NULL
dysregulation	NULL
of	NULL
PAX-5	NULL
gene	NULL
function	NULL
may	NULL
contribute	NULL
to	NULL
tumorigenesis	NULL
in	NULL
lymphoid	NULL
malignancies	NULL
.	NULL

We	NULL
report	NULL
here	NULL
results	NULL
from	NULL
an	NULL
immunohistochemical	NULL
study	NULL
of	NULL
BSAP	NULL
expression	NULL
in	NULL
reactive	NULL
lymphoid	NULL
tissues	NULL
and	NULL
neoplastic	NULL
lymphoid	NULL
tumors	NULL
,	NULL
using	NULL
a	NULL
specific	NULL
polyclonal	NULL
antisera	NULL
to	NULL
the	NULL
human	NULL
protein	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
hematolymphoid	NULL
cell	NULL
lines	NULL
,	NULL
including	NULL
those	NULL
representing	NULL
all	NULL
stages	NULL
of	NULL
B-cell	NULL
matura-tion	NULL
,	NULL
was	NULL
also	NULL
performed	NULL
.	NULL

We	NULL
found	NULL
that	NULL
BSAP	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
in	NULL
reactive	NULL
tissues	NULL
and	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
(	NULL
NHL	NULL
s	NULL
)	NULL
of	NULL
B-cell	NULL
lineage	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
role	NULL
for	NULL
BSAP	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
some	NULL
forms	NULL
of	NULL
human	NULL
NHLs	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Tissue	NULL
samples	NULL
.	NULL

Routinely	NULL
fixed	NULL
and	NULL
processed	NULL
malignant	NULL
lymphoma	NULL
and	NULL
reactive	NULL
lymphoid	NULL
tissue	NULL
samples	NULL
were	NULL
selected	NULL
from	NULL
the	NULL
histopathology	NULL
files	NULL
of	NULL
the	NULL
Hematopathology	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Pathology	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Albert	NULL
Szent-Gyorgyi	NULL
Medical	NULL
University	NULL
(	NULL
Szeged	NULL
,	NULL
Hungary	NULL
)	NULL
.	NULL

All	NULL
cases	NULL
included	NULL
in	NULL
the	NULL
study	NULL
were	NULL
classified	NULL
according	NULL
to	NULL
the	NULL
Revised	NULL
European-American	NULL
Classification	NULL
of	NULL
Lymphoid	NULL
Neoplasms	NULL
(	NULL
REAL	NULL
)	NULL
.	NULL
``	NULL

All	NULL
cases	NULL
had	NULL
been	NULL
previously	NULL
immunophenotyped	NULL
in	NULL
either	NULL
paraffin	NULL
or	NULL
frozen	NULL
section	NULL
immunohistochemistry	NULL
.	NULL

Polyclonal	NULL
CD3	NULL
(	NULL
DAKO	NULL
Corp	NULL
,	NULL
Carpinteria	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
CD15/LeuM1	NULL
(	NULL
Becton	NULL
Dickinson	NULL
[	NULL
BD	NULL
]	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
CD20/L26	NULL
(	NULL
DAKO	NULL
)	NULL
,	NULL
CD30/BerH2	NULL
(	NULL
DAKO	NULL
)	NULL
,	NULL
CD43/Leu22	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD45RO/A6	NULL
(	NULL
Zymed	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
€CD56/123C3	NULL
(	NULL
Mono-san/Caltag	NULL
Laboratories	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
CD68/KP1	NULL
(	NULL
DAKO	NULL
)	NULL
,	NULL
and	NULL
CD792/JCB117	NULL
(	NULL
DAKO	NULL
)	NULL
were	NULL
used	NULL
in	NULL
paraffin	NULL
sections	NULL
,	NULL
whereas	NULL
CD2/LeuSb	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD3/Leud	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD4/Leu3a	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD5/Leu1	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD7/Leu9	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD8/Leu2a	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD11b/Leu15	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD19/Leu12	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
CD22/Leu14	NULL
(	NULL
BD	NULL
)	NULL
,	NULL
and	NULL
CD56/Leu19	NULL
(	NULL
BD	NULL
)	NULL
were	NULL
used	NULL
for	NULL
frozen	NULL
sections	NULL
.	NULL

BSAP	NULL
antibodies	NULL
.	NULL

-	NULL
Polyclonal	NULL
antibodies	NULL
reactive	NULL
with	NULL
human	NULL
BSAP	NULL
were	NULL
generated	NULL
by	NULL
immunizing	NULL
rabbits	NULL
either	NULL
with	NULL
an	NULL
N-terminal	NULL
(	NULL
MDLEKNYPTPRTSRC	NULL
;	NULL
antibody	NULL
7077	NULL
)	NULL
or	NULL
a	NULL
C-terminal	NULL
peptide	NULL
(	NULL
CPPAAATAYDRH	NULL
;	NULL
antibody	NULL
7083	NULL
)	NULL
coupled	NULL
to	NULL
Keyhole	NULL
limpet	NULL
hemo-cyanin	NULL
(	NULL
KLH	NULL
)	NULL
.	NULL

These	NULL
antibodies	NULL
have	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
BSAP	NULL
protein	NULL
by	NULL
the	NULL
following	NULL
criteria	NULL
.	NULL

(	NULL
1	NULL
)	NULL
In	NULL
electromobil-ity	NULL
shift	NULL
assay	NULL
,	NULL
both	NULL
antibodies	NULL
supershifted	NULL
a	NULL
complex	NULL
formed	NULL
with	NULL
a	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
HS-Sultan	NULL
cells	NULL
and	NULL
a	NULL
DNA	NULL
probe	NULL
containing	NULL
a	NULL
high-affinity	NULL
BSAP	NULL
binding	NULL
site	NULL
.	NULL

(	NULL
2	NULL
)	NULL
Both	NULL
antisera	NULL
reacted	NULL
with	NULL
a	NULL
major	NULL
product	NULL
of	NULL
the	NULL
appropriate	NULL
molecular	NULL
weight	NULL
(	NULL
52	NULL
kD	NULL
)	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

(	NULL
3	NULL
)	NULL
Both	NULL
antisera	NULL
react	NULL
with	NULL
B	NULL
cells	NULL
and	NULL
not	NULL
T	NULL
cells	NULL
after	NULL
immunohistochemical	NULL
staining	NULL
of	NULL
lymphoid	NULL
tissue	NULL
(	NULL
A.	NULL
Riva	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

Immunohistochemical	NULL
detection	NULL
of	NULL
BSAP	NULL
.	NULL

-	NULL
For	NULL
immunohistochemical	NULL
detection	NULL
of	NULL
BSAP	NULL
,	NULL
antibody	NULL
7077	NULL
was	NULL
used	NULL
in	NULL
all	NULL
cases	NULL
,	NULL
whereas	NULL
antibody	NULL
7083	NULL
was	NULL
used	NULL
for	NULL
only	NULL
a	NULL
proportion	NULL
of	NULL
the	NULL
samples	NULL
.	NULL

All	NULL
immunoreactions	NULL
were	NULL
performed	NULL
after	NULL
microwave	NULL
antigen	NULL
retrieval	NULL
,	NULL
1309	NULL
according	NULL
to	NULL
a	NULL
protocol	NULL
modified	NULL
from	NULL
methods	NULL
previously	NULL
de-scribed	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
Briefly	NULL
,	NULL
the	NULL
antigen	NULL
retrieval	NULL
was	NULL
performed	NULL
for	NULL
40	NULL
minutes	NULL
in	NULL
a	NULL
microwave	NULL
pressure	NULL
cooker	NULL
(	NULL
Nordic	NULL
Ware	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
using	NULL
either	NULL
DAKO	NULL
Target	NULL
Retrieval	NULL
Solution	NULL
or	NULL
10	NULL
mmol/L	NULL
citrate	NULL
buffer	NULL
(	NULL
pH	NULL
6.0	NULL
)	NULL
containing	NULL
0.1	NULL
%	NULL
Tween-20	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

The	NULL
sections	NULL
were	NULL
incubated	NULL
overnight	NULL
with	NULL
7077	NULL
antiserum	NULL
(	NULL
1/1,000	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Immunoreactions	NULL
were	NULL
detected	NULL
with	NULL
biotinylated	NULL
swine	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
antirabbit	NULL
immunoglobulins	NULL
(	NULL
DAKO	NULL
;	NULL
1/400	NULL
)	NULL
and	NULL
streptavidin-peroxidase	NULL
conjugate	NULL
(	NULL
DAKO	NULL
;	NULL
1/600	NULL
)	NULL
.	NULL

The	NULL
peroxidase	NULL
reaction	NULL
was	NULL
developed	NULL
with	NULL
3,3	NULL
'	NULL
diaminobenzidine	NULL
tetrahydrochloride	NULL
(	NULL
DAB	NULL
;	NULL
Sigma	NULL
)	NULL
.	NULL

All	NULL
BSAP	NULL
immunostains	NULL
were	NULL
compared	NULL
with	NULL
consecutively	NULL
stained	NULL
conventional	NULL
hematoxylin	NULL
and	NULL
eosin	NULL
sections	NULL
as	NULL
well	NULL
as	NULL
with	NULL
sections	NULL
stained	NULL
with	NULL
CD20	NULL
and	NULL
CD3	NULL
to	NULL
determine	NULL
the	NULL
tissue	NULL
and	NULL
immunolocal-ization	NULL
of	NULL
BSAP	NULL
.	NULL

Double	NULL
immunostaining	NULL
was	NULL
also	NULL
performed	NULL
on	NULL
representative	NULL
reactive	NULL
lymph	NULL
nodes	NULL
and	NULL
cases	NULL
to	NULL
more	NULL
precisely	NULL
evaluate	NULL
coexpression	NULL
of	NULL
BSAP	NULL
with	NULL
B-	NULL
(	NULL
CD20	NULL
)	NULL
and	NULL
T-	NULL
(	NULL
CD3	NULL
)	NULL
cell	NULL
markers	NULL
.	NULL

For	NULL
these	NULL
reactions	NULL
,	NULL
BSAP	NULL
was	NULL
detected	NULL
as	NULL
described	NULL
above	NULL
,	NULL
except	NULL
that	NULL
the	NULL
reaction	NULL
was	NULL
developed	NULL
using	NULL
a	NULL
Peroxidase	NULL
Vectastain	NULL
Elite	NULL
ABC	NULL
kit	NULL
(	NULL
Vector	NULL
Laboratories	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
DAB	NULL
(	NULL
Sigma	NULL
)	NULL
to	NULL
generate	NULL
a	NULL
brown	NULL
precipitate	NULL
.	NULL

In	NULL
sequential	NULL
reactions	NULL
,	NULL
either	NULL
CD20	NULL
(	NULL
L26	NULL
)	NULL
or	NULL
CD3	NULL
was	NULL
detected	NULL
after	NULL
1	NULL
hour	NULL
of	NULL
incubation	NULL
with	NULL
the	NULL
primary	NULL
antibody	NULL
and	NULL
30	NULL
minutes	NULL
of	NULL
incubation	NULL
with	NULL
the	NULL
secondary	NULL
antibody	NULL
.	NULL

These	NULL
reactions	NULL
were	NULL
developed	NULL
using	NULL
the	NULL
Elite	NULL
ABC	NULL
kit	NULL
and	NULL
DAB	NULL
with	NULL
nickle	NULL
enhancement	NULL
to	NULL
generate	NULL
a	NULL
contrasting	NULL
black	NULL
precipitate	NULL
or	NULL
with	NULL
VIP	NULL
substrate	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
to	NULL
develop	NULL
a	NULL
contrasting	NULL
dark	NULL
purple	NULL
precipitate	NULL
.	NULL

Western	NULL
analysis	NULL
of	NULL
BSAP	NULL
.	NULL

-	NULL
Human	NULL
hematolymphoid	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
1	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
penicillin/streptomycin	NULL
,	NULL
and	NULL
2	NULL
mmol/L	NULL
L-glutamine	NULL
.	NULL

Exponentially	NULL
growing	NULL
cells	NULL
(	NULL
about	NULL
10°	NULL
cells/mL	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
protein	NULL
extraction	NULL
in	NULL
modified	NULL
RIPA	NULL
lysis	NULL
buffer	NULL
(	NULL
50	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
150	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
[	NULL
wt/vol	NULL
]	NULL
Na-deoxycholate	NULL
,	NULL
1	NULL
%	NULL
[	NULL
vol/vol	NULL
]	NULL
Nonidet	NULL
P-40	NULL
,	NULL
and	NULL
1	NULL
%	NULL
[	NULL
wt/vol	NULL
]	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
[	NULL
SDS	NULL
]	NULL
)	NULL
supplemented	NULL
with	NULL
proteinase	NULL
inhibitors	NULL
(	NULL
25	NULL
mg/mL	NULL
leupeptin	NULL
,	NULL
50	NULL
mg/mL	NULL
aprotinin	NULL
,	NULL
and	NULL
1	NULL
mmol/L	NULL
phenylmethylsulphonyl	NULL
fluoride	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
lysed	NULL
on	NULL
ice	NULL
,	NULL
and	NULL
the	NULL
lysates	NULL
were	NULL
vortexed	NULL
for	NULL
10	NULL
seconds	NULL
in	NULL
10-minute	NULL
intervals	NULL
for	NULL
a	NULL
total	NULL
time	NULL
of	NULL
60	NULL
minutes	NULL
.	NULL

The	NULL
protein	NULL
content	NULL
of	NULL
centrifuged	NULL
lysates	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
Bio-Rad	NULL
Protein	NULL
Assay	NULL
kit	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instruc-tions	NULL
.	NULL

Identical	NULL
amounts	NULL
(	NULL
75	NULL
mg	NULL
of	NULL
total	NULL
extracted	NULL
protein	NULL
)	NULL
were	NULL
boiled	NULL
in	NULL
Laemmili	NULL
's	NULL
sample	NULL
buffer	NULL
and	NULL
separated	NULL
by	NULL
electrophoresis	NULL
on	NULL
10	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
SDS-polyacrylamide	NULL
gels	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Schleicher	NULL
&	NULL
Schuell	NULL
,	NULL
Keene	NULL
,	NULL
NH	NULL
)	NULL
,	NULL
immunoblotting	NULL
was	NULL
performed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
blocked	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
TTBS	NULL
(	NULL
50	NULL
mmol/L	NULL
Tris-buffered	NULL
saline	NULL
,	NULL
pH	NULL
7.6	NULL
,	NULL
with	NULL
0.05	NULL
%	NULL
Tween-20	NULL
)	NULL
containing	NULL
5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
,	NULL
10	NULL
%	NULL
normal	NULL
goat	NULL
serum	NULL
(	NULL
GIBCO	NULL
Laboratories	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
NaN	NULL
.	NULL

The	NULL
nitrocellulose	NULL
membranes	NULL
were	NULL
probed	NULL
either	NULL
with	NULL
7077	NULL
or	NULL
7083	NULL
immunosera	NULL
(	NULL
both	NULL
diluted	NULL
in	NULL
1/1,000	NULL
)	NULL
and	NULL
developed	NULL
using	NULL
biotinylated	NULL
swine	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
;	NULL
antirabbit	NULL
Igs	NULL
(	NULL
1/10,000	NULL
;	NULL
Dako	NULL
)	NULL
,	NULL
streptavidin-peroxidase	NULL
conjugate	NULL
(	NULL
1/5,000	NULL
;	NULL
Dako	NULL
)	NULL
,	NULL
and	NULL
ECL	NULL
(	NULL
Amersham	NULL
Life	NULL
Science	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
detection	NULL
reagents	NULL
.	NULL

RESULTS	NULL
Use	NULL
of	NULL
BSAP	NULL
antisera	NULL
for	NULL
immunocytochemistry	NULL
.	NULL

-	NULL
To	NULL
test	NULL
the	NULL
reactivity	NULL
of	NULL
the	NULL
two	NULL
BSAP	NULL
antisera	NULL
,	NULL
7083	NULL
and	NULL
7077	NULL
,	NULL
in	NULL
paraffin-embedded	NULL
formalin-fixed	NULL
tissues	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
antisera	NULL
to	NULL
appropriately	NULL
mark	NULL
reactive	NULL
lymphoid	NULL
tissues	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
known	NULL
nuclear	NULL
location	NULL
of	NULL
BSAP	NULL
,	NULL
a	NULL
specific	NULL
immunoreaction	NULL
was	NULL
observed	NULL
only	NULL
in	NULL
nuclei	NULL
within	NULL
B-cell	NULL
zones	NULL
and	NULL
in	NULL
lymph	NULL
node	NULL
,	NULL
tonsil	NULL
,	NULL
and	NULL
spleen	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
initial	NULL
studies	NULL
established	NULL
that	NULL
mantle	NULL
zone	NULL
B	NULL
cells	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1310	NULL
have	NULL
a	NULL
consistently	NULL
high	NULL
level	NULL
of	NULL
BSAP	NULL
expression	NULL
,	NULL
allowing	NULL
these	NULL
or	NULL
residual	NULL
mantle	NULL
cells	NULL
in	NULL
the	NULL
subsequent	NULL
stained	NULL
tumor	NULL
sections	NULL
to	NULL
serve	NULL
as	NULL
endogenous	NULL
controls	NULL
in	NULL
all	NULL
BSAP	NULL
immunoreactions	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

The	NULL
strong	NULL
positivity	NULL
of	NULL
normal	NULL
mantle	NULL
zone	NULL
*	NULL
F	NULL
$	NULL
w4*	NULL
``	NULL
mente	NULL
e	NULL
+s	NULL
8	NULL
casin	NULL
*	NULL
KRENACS	NULL
ET	NULL
AL	NULL
cells	NULL
and	NULL
scattered	NULL
(	NULL
residual	NULL
)	NULL
small	NULL
B	NULL
lymphocytes	NULL
was	NULL
also	NULL
used	NULL
to	NULL
evaluate	NULL
the	NULL
relative	NULL
staining	NULL
intensity	NULL
of	NULL
other	NULL
BSAP-positive	NULL
cells	NULL
as	NULL
follows	NULL
:	NULL
strong	NULL
BSAP	NULL
expression	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
staining	NULL
of	NULL
mantle	NULL
zone	NULL
cells	NULL
;	NULL
moderate	NULL
expression	NULL
,	NULL
Oi	NULL
‘	NULL
qzv	NULL
'	NULL
B..	NULL
®	NULL
&	NULL
i	NULL
‘	NULL
Z	NULL
®	NULL
#	NULL
‘	NULL
r	NULL
6	NULL
}	NULL
a	NULL
#	NULL
#	NULL
#	NULL
8	NULL
,	NULL
*	NULL
>	NULL
6	NULL
.	NULL

_	NULL
``	NULL
°	NULL
%	NULL
&	NULL
*	NULL
%	NULL
9	NULL
#	NULL
*	NULL
®	NULL
#	NULL
«	NULL
€	NULL
``	NULL
m	NULL
35	NULL
?	NULL

®	NULL
,	NULL
_-	NULL
»	NULL
s	NULL
*	NULL
o	NULL
*	NULL
i	NULL
)	NULL
g	NULL
,	NULL
.	NULL

r	NULL
%	NULL
%	NULL
‘	NULL
2	NULL
A	NULL
»	NULL
4	NULL
&	NULL
“	NULL
a	NULL
;	NULL
¢..	NULL
‘	NULL
n	NULL
#	NULL
**	NULL
,	NULL
go	NULL
&	NULL
a*	NULL
b	NULL
i	NULL
a	NULL
aoe	NULL
ep	NULL
‘	NULL
E	NULL
J	NULL
r	NULL
s	NULL
I	NULL
«	NULL
ae	NULL
s	NULL
%	NULL
w	NULL
*	NULL
B	NULL
*	NULL
u	NULL
“	NULL
[	NULL
3	NULL
,	NULL
%	NULL
s*	NULL
*	NULL
``	NULL
mg	NULL
)	NULL
e	NULL
R	NULL
``	NULL
»	NULL
x	NULL
‘	NULL
ﬁ	NULL
``	NULL
;	NULL
B	NULL
*-	NULL
<	NULL
T	NULL
«	NULL
$	NULL
%	NULL
e	NULL
‘	NULL
7	NULL
(	NULL
n	NULL
``	NULL
‘	NULL
n	NULL
Fas	NULL
*	NULL
|	NULL
din	NULL
®	NULL
F3	NULL
%	NULL
*	NULL
x	NULL
3	NULL
[	NULL
1a	NULL
%	NULL
©	NULL
ap	NULL
<	NULL
&	NULL
s	NULL
3	NULL
8	NULL
:	NULL
%	NULL
%	NULL
‘	NULL
4	NULL
Fig	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Hyperplasticlymph	NULL
node	NULL
show	NULL
ing	NULL
BSAP	NULL
expression	NULL
primarily	NULL
restricted	NULL
to	NULL
follicular	NULL
regions	NULL
,	NULL
with	NULL
strong	NULL
nuclear	NULL
staining	NULL
present	NULL
in	NULL
mantle	NULL
zone	NULL
cells	NULL
and	NULL
less	NULL
intense	NULL
staining	NULL
in	NULL
follicle	NULL
center	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
through	NULL
D	NULL
)	NULL
Lymphomas	NULL
with	NULL
strong	NULL
BSAP	NULL
expression	NULL
:	NULL
(	NULL
B	NULL
)	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
,	NULL
(	NULL
C	NULL
)	NULL
FL	NULL
,	NULL
and	NULL
(	NULL
D	NULL
)	NULL
mediastinal	NULL
large	NULL
B-cell	NULL
lymphoma	NULL
.	NULL

(	NULL
E	NULL
and	NULL
F	NULL
)	NULL
Lymphomas	NULL
with	NULL
no	NULL
BSAP	NULL
expression	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Primary	NULL
monocytoid	NULL
B-cell	NULL
(	NULL
M	NULL
ALT-	NULL
)	NULL
lymphoma	NULL
of	NULL
parotid	NULL
gland	NULL
and	NULL
(	NULL
F	NULL
)	NULL
angicimmunoblastic	NULL
T-cell	NULL
lymphoma	NULL
.	NULL

Note	NULL
the	NULL
positive	NULL
control	NULL
staining	NULL
of	NULL
residual	NULL
mantle	NULL
zone	NULL
cells	NULL
and	NULL
normal	NULL
B	NULL
cells	NULL
in	NULL
the	NULL
negative	NULL
cases	NULL
.	NULL

(	NULL
Streptavidin-bictin-peroxidase	NULL
method	NULL
;	NULL
original	NULL
magnification	NULL
[	NULL
A	NULL
]	NULL
x	NULL
200	NULL
,	NULL
[	NULL
B	NULL
]	NULL
x400	NULL
,	NULL
[	NULL
C	NULL
]	NULL
x200	NULL
,	NULL
[	NULL
D	NULL
]	NULL
x600	NULL
,	NULL
[	NULL
E	NULL
]	NULL
x200	NULL
,	NULL
and	NULL
[	NULL
F	NULL
]	NULL
x400	NULL
.	NULL
)	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BSAP	NULL
EXPRESSION	NULL
IN	NULL
LYMPHOID	NULL
MALIGNANCIES	NULL
weaker	NULL
but	NULL
significant	NULL
reaction	NULL
intensity	NULL
;	NULL
and	NULL
weak	NULL
expression	NULL
,	NULL
detectable	NULL
nuclear	NULL
staining	NULL
above	NULL
the	NULL
background	NULL
level	NULL
.	NULL

Double-staining	NULL
with	NULL
antibodies	NULL
directed	NULL
against	NULL
B-	NULL
or	NULL
T-cell-associated	NULL
antigens	NULL
clearly	NULL
identified	NULL
the	NULL
BSAP-positive	NULL
cells	NULL
as	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
either	NULL
the	NULL
amino-terminus-specific	NULL
7077	NULL
or	NULL
the	NULL
carboxy-terminus-spe-cific	NULL
7083	NULL
antiserum	NULL
.	NULL

However	NULL
,	NULL
because	NULL
of	NULL
its	NULL
clearer	NULL
reaction	NULL
pattern	NULL
,	NULL
antibody	NULL
7077	NULL
was	NULL
systematically	NULL
used	NULL
in	NULL
the	NULL
study	NULL
.	NULL

Two	NULL
hundred	NULL
twenty-eight	NULL
cases	NULL
were	NULL
collected	NULL
in	NULL
the	NULL
initial	NULL
group	NULL
.	NULL

Seventy-three	NULL
of	NULL
these	NULL
cases	NULL
showed	NULL
poor	NULL
or	NULL
no	NULL
BSAP	NULL
immunoreaction	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
residual	NULL
small	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
therefore	NULL
were	NULL
excluded	NULL
from	NULL
further	NULL
evaluation	NULL
.	NULL

These	NULL
technically	NULL
negative	NULL
samples	NULL
included	NULL
either	NULL
cases	NULL
fixed	NULL
in	NULL
B5	NULL
or	NULL
those	NULL
for	NULL
which	NULL
only	NULL
unstained	NULL
paraffin	NULL
slides	NULL
stored	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
years	NULL
were	NULL
available	NULL
for	NULL
study	NULL
.	NULL

The	NULL
loss	NULL
of	NULL
immunoreactivity	NULL
over	NULL
time	NULL
in	NULL
paraffin	NULL
sections	NULL
(	NULL
especially	NULL
in	NULL
B5-fixed	NULL
tissues	NULL
)	NULL
is	NULL
well	NULL
documented	NULL
with	NULL
some	NULL
nuclear	NULL
and	NULL
nonnuclear	NULL
antigens	NULL
.	NULL
``	NULL

''	NULL
Among	NULL
the	NULL
155	NULL
cases	NULL
judged	NULL
to	NULL
be	NULL
appropriate	NULL
for	NULL
evaluation	NULL
of	NULL
BSAP	NULL
expression	NULL
,	NULL
there	NULL
were	NULL
12	NULL
hyperplastic	NULL
lymphatic	NULL
tissues	NULL
(	NULL
including	NULL
nonspecific	NULL
follicular	NULL
hyperplasias	NULL
of	NULL
3	NULL
tonsils	NULL
and	NULL
7	NULL
lymph	NULL
nodes	NULL
,	NULL
and	NULL
2	NULL
cases	NULL
of	NULL
Toxoplasma	NULL
lymphadenitis	NULL
)	NULL
,	NULL
102	NULL
B-cell	NULL
lymphomas	NULL
,	NULL
23	NULL
non-B-cell	NULL
lymphomas	NULL
including	NULL
12	NULL
peripheral	NULL
T-cell	NULL
lymphomas	NULL
(	NULL
PTCLs	NULL
)	NULL
,	NULL
3	NULL
precursor	NULL
T-cell	NULL
leuke-mia/lymphomas	NULL
,	NULL
8	NULL
anaplastic	NULL
large-cell	NULL
lymphomas	NULL
of	NULL
T-	NULL
and	NULL
null-cell	NULL
types	NULL
(	NULL
ALCL	NULL
)	NULL
,	NULL
and	NULL
18	NULL
cases	NULL
of	NULL
Hodgkin	NULL
's	NULL
disease	NULL
(	NULL
HD	NULL
)	NULL
.	NULL

Reactive	NULL
lymphoid	NULL
tissues	NULL
.	NULL

-	NULL
In	NULL
addition	NULL
to	NULL
the	NULL
homogenous	NULL
strong	NULL
BSAP	NULL
staining	NULL
found	NULL
in	NULL
mantle	NULL
zone	NULL
cells	NULL
,	NULL
follicular	NULL
center	NULL
(	NULL
FC	NULL
)	NULL
B	NULL
cells	NULL
displayed	NULL
a	NULL
variable	NULL
but	NULL
usually	NULL
less	NULL
intense	NULL
,	NULL
weak	NULL
to	NULL
moderate	NULL
,	NULL
BSAP	NULL
reaction	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Weak	NULL
to	NULL
moderate	NULL
nuclear	NULL
staining	NULL
was	NULL
found	NULL
in	NULL
the	NULL
dark	NULL
zone	NULL
centroblasts	NULL
and	NULL
in	NULL
some	NULL
light	NULL
zone	NULL
centrocytes	NULL
,	NULL
whereas	NULL
weak	NULL
reactions	NULL
occurred	NULL
in	NULL
most	NULL
light	NULL
zone	NULL
FC	NULL
B	NULL
cells	NULL
,	NULL
reflecting	NULL
the	NULL
characteristic	NULL
polarization	NULL
of	NULL
reactive	NULL
follicles	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
normal	NULL
monocytoid	NULL
B	NULL
cells	NULL
characteristically	NULL
seen	NULL
in	NULL
cases	NULL
of	NULL
toxoplasma	NULL
lymphadenitis	NULL
were	NULL
negative	NULL
,	NULL
but	NULL
rare	NULL
cells	NULL
demonstrated	NULL
weak	NULL
reactions	NULL
.	NULL

No	NULL
staining	NULL
occurred	NULL
in	NULL
plasma	NULL
cells	NULL
,	NULL
extrafollicular	NULL
large	NULL
B	NULL
cells	NULL
,	NULL
histiocytes	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

B-cell	NULL
NHL	NULL
s.	NULL
-	NULL
Overall	NULL
,	NULL
81	NULL
%	NULL
(	NULL
83/102	NULL
)	NULL
of	NULL
the	NULL
B-cell	NULL
lymphomas	NULL
demonstrated	NULL
BSAP	NULL
positivity	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

With	NULL
rare	NULL
excep-tions	NULL
,	NULL
all	NULL
tumor	NULL
cells	NULL
in	NULL
positive	NULL
cases	NULL
showed	NULL
BSAP	NULL
expression	NULL
.	NULL

Weak	NULL
expression	NULL
of	NULL
BSAP	NULL
was	NULL
found	NULL
in	NULL
tumor	NULL
cells	NULL
in	NULL
1	NULL
of	NULL
the	NULL
2	NULL
precursor	NULL
B-cell	NULL
leukemia/lymphoma	NULL
cases	NULL
tested	NULL
.	NULL

All	NULL
13	NULL
cases	NULL
(	NULL
100	NULL
%	NULL
)	NULL
of	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia/small	NULL
lymphocytic	NULL
lymphoma	NULL
(	NULL
CLL/SLL	NULL
)	NULL
expressed	NULL
BSAP	NULL
and	NULL
most	NULL
stained	NULL
with	NULL
moderate	NULL
intensity	NULL
.	NULL

Cells	NULL
of	NULL
proliferation	NULL
centers	NULL
usually	NULL
displayed	NULL
less	NULL
intense	NULL
,	NULL
negative	NULL
to	NULL
weak	NULL
,	NULL
BSAP	NULL
expression	NULL
,	NULL
although	NULL
in	NULL
1	NULL
case	NULL
,	NULL
small	NULL
cells	NULL
were	NULL
negative	NULL
,	NULL
whereas	NULL
prolymphocytes	NULL
and	NULL
paraimmunoblasts	NULL
showed	NULL
moderate	NULL
BSAP	NULL
reac-tivity	NULL
.	NULL

BSAP	NULL
expression	NULL
was	NULL
demonstrated	NULL
in	NULL
21	NULL
of	NULL
21	NULL
(	NULL
100	NULL
%	NULL
)	NULL
mantle	NULL
cell	NULL
lymphomas	NULL
(	NULL
MCLs	NULL
)	NULL
,	NULL
with	NULL
strong	NULL
reactions	NULL
occurring	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
cases	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Double-staining	NULL
experiments	NULL
demonstrated	NULL
that	NULL
BSAP	NULL
was	NULL
present	NULL
exclusively	NULL
in	NULL
CD20+	NULL
tumor	NULL
cells	NULL
(	NULL
Fig	NULL
2C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Only	NULL
1	NULL
of	NULL
the	NULL
21	NULL
FLs	NULL
(	NULL
5	NULL
%	NULL
)	NULL
was	NULL
BSAP-negative	NULL
.	NULL

Of	NULL
the	NULL
20	NULL
positive	NULL
cases	NULL
,	NULL
2	NULL
(	NULL
both	NULL
grade	NULL
III	NULL
cases	NULL
[	NULL
10	NULL
%	NULL
]	NULL
)	NULL
showed	NULL
weak	NULL
BSAP	NULL
expression	NULL
,	NULL
11	NULL
(	NULL
1	NULL
grade	NULL
I	NULL
,	NULL
8	NULL
grade	NULL
II	NULL
,	NULL
and	NULL
2	NULL
grade	NULL
III	NULL
cases	NULL
[	NULL
55	NULL
%	NULL
]	NULL
)	NULL
displayed	NULL
moderate	NULL
expression	NULL
and	NULL
7	NULL
(	NULL
1	NULL
grade	NULL
I	NULL
,	NULL
2	NULL
grade	NULL
II	NULL
,	NULL
and	NULL
4	NULL
grade	NULL
III	NULL
cases	NULL
[	NULL
35	NULL
%	NULL
]	NULL
)	NULL
were	NULL
strongly	NULL
BSAP-positive	NULL
(	NULL
Fig	NULL
1C	NULL
)	NULL
.	NULL

Loss	NULL
of	NULL
polariza-	NULL
1311	NULL
tion	NULL
of	NULL
neoplastic	NULL
follicles	NULL
was	NULL
clearly	NULL
seen	NULL
with	NULL
BSAP	NULL
staining	NULL
(	NULL
Fig	NULL
1C	NULL
)	NULL
.	NULL

Double-staining	NULL
studies	NULL
showed	NULL
that	NULL
only	NULL
the	NULL
CD20+*	NULL
B	NULL
cells	NULL
expressed	NULL
BSAP	NULL
,	NULL
whereas	NULL
the	NULL
occasional	NULL
intratumoral	NULL
CD3	NULL
*	NULL
cell	NULL
and	NULL
dendritic	NULL
cell	NULL
were	NULL
negative	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
(	NULL
Fig	NULL
2G	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
12	NULL
marginal	NULL
zone	NULL
B-cell	NULL
lymphomas	NULL
tested	NULL
,	NULL
5	NULL
(	NULL
42	NULL
%	NULL
)	NULL
were	NULL
negative	NULL
and	NULL
3	NULL
(	NULL
25	NULL
%	NULL
)	NULL
were	NULL
weakly	NULL
,	NULL
3	NULL
(	NULL
25	NULL
%	NULL
)	NULL
were	NULL
moderately	NULL
,	NULL
and	NULL
1	NULL
(	NULL
8	NULL
%	NULL
)	NULL
was	NULL
strongly	NULL
BSAP-positive	NULL
.	NULL

Four	NULL
of	NULL
the	NULL
5	NULL
monocytoid	NULL
B-cell	NULL
lymphomas	NULL
of	NULL
the	NULL
parotid	NULL
were	NULL
either	NULL
negative	NULL
or	NULL
weakly	NULL
focally	NULL
positive	NULL
(	NULL
Fig	NULL
1E	NULL
)	NULL
.	NULL

Nuclear	NULL
staining	NULL
was	NULL
not	NULL
demonstrated	NULL
in	NULL
5	NULL
plasmacytomas	NULL
tested	NULL
,	NULL
including	NULL
2	NULL
cases	NULL
of	NULL
myeloma	NULL
and	NULL
3	NULL
extramedullary	NULL
plasmacytomas	NULL
.	NULL

Of	NULL
the	NULL
2	NULL
lymphoplasmacytoid	NULL
lymphoma	NULL
(	NULL
im-munocytoma	NULL
)	NULL
cases	NULL
,	NULL
1	NULL
showed	NULL
a	NULL
positive	NULL
BSAP	NULL
reaction	NULL
.	NULL

Nineteen	NULL
(	NULL
79	NULL
%	NULL
)	NULL
of	NULL
24	NULL
diffuse	NULL
large	NULL
B-cell	NULL
lymphomas	NULL
(	NULL
LBCL	NULL
)	NULL
displayed	NULL
BSAP	NULL
expression	NULL
of	NULL
moderate	NULL
to	NULL
strong	NULL
intensity	NULL
,	NULL
including	NULL
3	NULL
of	NULL
3	NULL
(	NULL
100	NULL
%	NULL
)	NULL
cases	NULL
of	NULL
mediastinal	NULL
LBCL	NULL
with	NULL
strong	NULL
positivity	NULL
(	NULL
Fig	NULL
1D	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
double-staining	NULL
studies	NULL
indicated	NULL
that	NULL
only	NULL
the	NULL
CD20+*	NULL
tumor	NULL
cells	NULL
contained	NULL
detectable	NULL
BSAP	NULL
(	NULL
Fig	NULL
2E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

BSAP	NULL
levels	NULL
in	NULL
T-	NULL
and	NULL
null-cell	NULL
NHLs	NULL
and	NULL
HD	NULL
.	NULL

BSAP	NULL
immunoreactivity	NULL
was	NULL
not	NULL
seen	NULL
in	NULL
8	NULL
anaplastic	NULL
large-cell	NULL
lymphomas	NULL
of	NULL
T-	NULL
and	NULL
null-cell	NULL
types	NULL
,	NULL
in	NULL
12	NULL
nonanaplastic	NULL
peripheral	NULL
T-cell	NULL
lymphomas	NULL
(	NULL
Figs	NULL
1E	NULL
and	NULL
2H	NULL
)	NULL
,	NULL
or	NULL
in	NULL
the	NULL
3	NULL
cases	NULL
of	NULL
T-cell	NULL
lymphoblastic	NULL
lymphoma	NULL
.	NULL

Of	NULL
the	NULL
18	NULL
cases	NULL
of	NULL
HD	NULL
,	NULL
7	NULL
(	NULL
39	NULL
%	NULL
)	NULL
showed	NULL
weak	NULL
nuclear	NULL
or	NULL
nucleolar	NULL
positivity	NULL
in	NULL
a	NULL
fraction	NULL
of	NULL
tumor	NULL
cells	NULL
,	NULL
including	NULL
2	NULL
of	NULL
4	NULL
(	NULL
50	NULL
%	NULL
)	NULL
nodular	NULL
lymphocytic	NULL
predominance	NULL
(	NULL
LP	NULL
)	NULL
and	NULL
5	NULL
of	NULL
14	NULL
(	NULL
36	NULL
%	NULL
)	NULL
classical	NULL
cases	NULL
(	NULL
4	NULL
nodular	NULL
sclerosis	NULL
and	NULL
1	NULL
lymphocyte-depleted	NULL
subtype	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
for	NULL
BSAP	NULL
.	NULL

-	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
the	NULL
7077	NULL
antibody	NULL
demonstrated	NULL
a	NULL
specific	NULL
protein	NULL
band	NULL
of	NULL
the	NULL
expected	NULL
size	NULL
(	NULL
52	NULL
kD	NULL
)	NULL
in	NULL
cell	NULL
lines	NULL
corresponding	NULL
to	NULL
precursor	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
terminally	NULL
differentiated	NULL
plasma	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
other	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
2	NULL
and	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
carboxy	NULL
terminus-specific	NULL
7083	NULL
antibody	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
tested	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
pre-B-cell	NULL
line	NULL
PB-697	NULL
also	NULL
displayed	NULL
an	NULL
intense	NULL
band	NULL
of	NULL
46	NULL
kD	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
that	NULL
was	NULL
only	NULL
detected	NULL
with	NULL
the	NULL
7077	NULL
antisera	NULL
.	NULL

The	NULL
pre-B-cell	NULL
line	NULL
Nalm-6	NULL
had	NULL
a	NULL
similar	NULL
46-kD	NULL
band	NULL
,	NULL
although	NULL
at	NULL
a	NULL
much	NULL
lower	NULL
intensity	NULL
.	NULL

However	NULL
,	NULL
gel	NULL
shift	NULL
analysis	NULL
of	NULL
PB-697	NULL
nuclear	NULL
extracts	NULL
did	NULL
not	NULL
show	NULL
an	NULL
additional	NULL
BSAP	NULL
gel	NULL
shift	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
immunoblotting	NULL
of	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
indicated	NULL
that	NULL
the	NULL
46-kD	NULL
protein	NULL
resides	NULL
in	NULL
the	NULL
cytoplasm	NULL
rather	NULL
than	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

Furthermore	NULL
,	NULL
reverse	NULL
transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
and	NULL
sequencing	NULL
of	NULL
BSAP	NULL
from	NULL
PB697	NULL
cells	NULL
failed	NULL
to	NULL
identify	NULL
a	NULL
novel	NULL
mRNA	NULL
transcript	NULL
or	NULL
evidence	NULL
for	NULL
a	NULL
frame	NULL
shift	NULL
mutation	NULL
(	NULL
A.	NULL
Rivas	NULL
,	NULL
unpublished	NULL
observation	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
band	NULL
is	NULL
unlikely	NULL
to	NULL
represent	NULL
a	NULL
c-terminally	NULL
truncated	NULL
form	NULL
of	NULL
BSAP	NULL
,	NULL
as	NULL
recently	NULL
described	NULL
in	NULL
the	NULL
human	NULL
pro-B-cell	NULL
line	NULL
REH	NULL
.	NULL

DISCUSSION	NULL
Using	NULL
two	NULL
polyclonal	NULL
BSAP	NULL
antisera	NULL
,	NULL
we	NULL
evaluated	NULL
the	NULL
expression	NULL
of	NULL
BSAP	NULL
in	NULL
reactive	NULL
and	NULL
neoplastic	NULL
lymphoid	NULL
tissues	NULL
by	NULL
immunocytochemistry	NULL
and	NULL
in	NULL
representative	NULL
B-cell	NULL
and	NULL
non-B-cell	NULL
lines	NULL
by	NULL
immunoblotting	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
tissue	NULL
B	NULL
cells	NULL
and	NULL
greater	NULL
than	NULL
80	NULL
%	NULL
of	NULL
the	NULL
B-cell	NULL
lymphomas	NULL
reacted	NULL
with	NULL
the	NULL
BSAP	NULL
antisera	NULL
.	NULL

Double-staining	NULL
studies	NULL
demonstrated	NULL
that	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
BSAP-positive	NULL
cells	NULL
coexpressed	NULL
CD20	NULL
and	NULL
that	NULL
few	NULL
,	NULL
if	NULL
any	NULL
,	NULL
expressed	NULL
CD3	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
BSAP	NULL
expression	NULL
varied	NULL
among	NULL
different	NULL
B-cell	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1312	NULL
KRENACS	NULL
ET	NULL
AL	NULL
,	NULL
'	NULL
%	NULL
'	NULL
a	NULL
J	NULL
*A	NULL
Ahad	NULL
esh	NULL
Colt	NULL
&	NULL
r	NULL
}	NULL
-	NULL
‘	NULL
*_._	NULL
‘	NULL
&	NULL
ﬁyam	NULL
%	NULL
¢	NULL
``	NULL
&	NULL
:	NULL
a	NULL
#	NULL
”	NULL
Wain	NULL
;	NULL
h	NULL
“	NULL
H	NULL
’	NULL
s	NULL
;	NULL
-	NULL
i	NULL
K	NULL
*	NULL
cs	NULL
.	NULL

q	NULL
``	NULL
y	NULL
apn	NULL
«	NULL
*+	NULL
KF	NULL
uly	NULL
‘	NULL
ix	NULL
‘	NULL
i	NULL
``	NULL
%	NULL
(	NULL
n	NULL
3	NULL
'	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BSAP	NULL
EXPRESSION	NULL
IN	NULL
LYMPHOID	NULL
MALIGNANCIES	NULL
Table	NULL
1	NULL
.	NULL

BSAP	NULL
Expression	NULL
in	NULL
Malignant	NULL
Lymphomas	NULL
BSAP	NULL
Positivity	NULL
Cases	NULL
Negative	NULL
+	NULL
++	NULL
+++	NULL
Overall	NULL
Positivity	NULL
B-LB/ALL	NULL
1	NULL
1	NULL
-	NULL
-	NULL
1/2	NULL
(	NULL
50	NULL
%	NULL
)	NULL
B-CLL/SLL	NULL
-	NULL
3	NULL
6	NULL
4	NULL
13/13	NULL
(	NULL
100	NULL
%	NULL
)	NULL
MCL	NULL
-	NULL
1	NULL
7	NULL
13	NULL
21/21	NULL
(	NULL
100	NULL
%	NULL
)	NULL
FCL	NULL
1	NULL
2	NULL
11	NULL
7	NULL
20/21	NULL
(	NULL
95	NULL
%	NULL
)	NULL
Marginal	NULL
zone	NULL
5	NULL
3	NULL
3	NULL
1	NULL
7/12	NULL
(	NULL
58	NULL
%	NULL
)	NULL
Immunocytoma	NULL
1	NULL
-	NULL
1	NULL
-	NULL
1/2	NULL
(	NULL
50	NULL
%	NULL
)	NULL
Plasmacytoma	NULL
5	NULL
-	NULL
-	NULL
-	NULL
0/5	NULL
Diffuse	NULL
LBCL	NULL
5	NULL
2	NULL
7	NULL
10	NULL
19/24	NULL
(	NULL
79	NULL
%	NULL
)	NULL
Burkitt	NULL
's	NULL
1	NULL
-	NULL
1	NULL
-	NULL
1/2	NULL
(	NULL
50	NULL
%	NULL
)	NULL
T-LB	NULL
3	NULL
-	NULL
-	NULL
-	NULL
0/3	NULL
PTCL	NULL
12	NULL
-	NULL
-	NULL
0/12	NULL
ALCL	NULL
3	NULL
-	NULL
-	NULL
-	NULL
0/8	NULL
HD-LP	NULL
2	NULL
2	NULL
-	NULL
-	NULL
2/4	NULL
(	NULL
50	NULL
%	NULL
)	NULL
HD-Classical	NULL
9	NULL
5*	NULL
-	NULL
-	NULL
5/14	NULL
(	NULL
36	NULL
%	NULL
)	NULL
Abbreviations	NULL
:	NULL
B-LB/ALL	NULL
,	NULL
B-lymphoblastic	NULL
lymphom	NULL
a/acute	NULL
lymphoblastic	NULL
leukemia	NULL
;	NULL
B-CLL	NULL
,	NULL
B-cell	NULL
chronic	NULL
lymphocytic	NULL
leukemia/small	NULL
lymphocytic	NULL
lymphoma	NULL
;	NULL
MCL	NULL
,	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
;	NULL
FCL	NULL
,	NULL
follicle	NULL
center	NULL
lymphoma	NULL
;	NULL
LBCL	NULL
,	NULL
large	NULL
B-cell	NULL
lymphoma	NULL
;	NULL
TCRBCL	NULL
,	NULL
T-cell-rich	NULL
B-cell	NULL
lymphoma	NULL
;	NULL
T-LB	NULL
,	NULL
T-lymphoblastic	NULL
lymphoma	NULL
;	NULL
PTCL	NULL
,	NULL
peripheral	NULL
T-cell	NULL
lymphoma	NULL
;	NULL
ALCL	NULL
,	NULL
anaplastic	NULL
large-cell	NULL
lymphoma	NULL
;	NULL
HD-LP	NULL
,	NULL
Hodgkin	NULL
's	NULL
disease	NULL
of	NULL
lymphocytic	NULL
predominance	NULL
type	NULL
.	NULL

*	NULL
Focal	NULL
nucleolar	NULL
staining	NULL
.	NULL

subsets	NULL
and	NULL
among	NULL
B-cell	NULL
NHL	NULL
subtypes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
40	NULL
%	NULL
of	NULL
the	NULL
HD	NULL
cases	NULL
tested	NULL
had	NULL
weak	NULL
BSAP	NULL
expression	NULL
in	NULL
occasional	NULL
tumor	NULL
cells	NULL
.	NULL

In	NULL
comparison	NULL
,	NULL
normal	NULL
or	NULL
neoplastic	NULL
T	NULL
cells	NULL
and	NULL
other	NULL
hematolymphoid	NULL
tissues	NULL
consistently	NULL
lacked	NULL
BSAP	NULL
.	NULL

To	NULL
the	NULL
best	NULL
of	NULL
our	NULL
knowledge	NULL
,	NULL
this	NULL
is	NULL
the	NULL
first	NULL
study	NULL
of	NULL
in	NULL
vivo	NULL
BSAP	NULL
expression	NULL
in	NULL
primary	NULL
tumor	NULL
samples	NULL
of	NULL
malignant	NULL
lymphomas	NULL
.	NULL

In	NULL
reactive	NULL
lymphoid	NULL
tissues	NULL
,	NULL
BSAP	NULL
expression	NULL
was	NULL
found	NULL
only	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
B	NULL
lymphocytes	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
different	NULL
B-cell	NULL
compartments	NULL
displayed	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
intensities	NULL
of	NULL
their	NULL
BSAP	NULL
immunoreactivity	NULL
.	NULL

Cells	NULL
of	NULL
the	NULL
follicular	NULL
mantle	NULL
contained	NULL
the	NULL
highest	NULL
levels	NULL
of	NULL
BSAP	NULL
,	NULL
whereas	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
had	NULL
considerably	NULL
lower	NULL
levels	NULL
.	NULL

Extrafollicular	NULL
transformed	NULL
B	NULL
cells	NULL
(	NULL
immunoblasts	NULL
)	NULL
,	NULL
along	NULL
with	NULL
plasma	NULL
cells	NULL
,	NULL
lacked	NULL
detectable	NULL
immunoreactivity	NULL
.	NULL

The	NULL
high	NULL
BSAP	NULL
levels	NULL
found	NULL
in	NULL
mantle	NULL
zone	NULL
B	NULL
cells	NULL
relative	NULL
to	NULL
the	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
is	NULL
curious	NULL
because	NULL
of	NULL
the	NULL
purported	NULL
role	NULL
of	NULL
BSAP	NULL
in	NULL
B-cell	NULL
proliferation	NULL
and	NULL
promoting	NULL
Ig	NULL
class	NULL
switching	NULL
.	NULL

**	NULL
``	NULL
'	NULL
Because	NULL
switch	NULL
recombination	NULL
apparently	NULL
requires	NULL
cell	NULL
divi-sion	NULL
``	NULL
``	NULL
and	NULL
is	NULL
believed	NULL
to	NULL
occur	NULL
in	NULL
the	NULL
germinal	NULL
center	NULL
large	NULL
cells	NULL
(	NULL
centroblasts	NULL
)	NULL
,4	NULL
'	NULL
one	NULL
might	NULL
have	NULL
expected	NULL
high	NULL
BSAP	NULL
levels	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
the	NULL
decline	NULL
of	NULL
BSAP	NULL
levels	NULL
in	NULL
the	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
mantle	NULL
zone	NULL
B	NULL
cells	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
BSAP	NULL
suggests	NULL
the	NULL
presence	NULL
of	NULL
important	NULL
BSAP	NULL
target	NULL
genes	NULL
in	NULL
these	NULL
1313	NULL
Table	NULL
2	NULL
.	NULL

Hematolymphoid	NULL
Cell	NULL
Lines	NULL
Tested	NULL
With	NULL
Western	NULL
Blot	NULL
for	NULL
BSAP	NULL
Expression	NULL
BSAP	NULL
Cell	NULL
Line	NULL
Origin/Cell	NULL
Type	NULL
(	NULL
revised	NULL
)	NULL
Expression	NULL
K-562	NULL
Erythroleukemia	NULL
Negative	NULL
Jurkat	NULL
T-ALL	NULL
Negative	NULL
H9	NULL
Sezary	NULL
's	NULL
syndrome	NULL
Negative	NULL
SU-DHL-1	NULL
Anaplastic	NULL
large	NULL
cell	NULL
lymphoma	NULL
Negative	NULL
Karpas	NULL
299	NULL
Anaplastic	NULL
large	NULL
cell	NULL
lymphoma	NULL
Negative	NULL
YT	NULL
ALL	NULL
with	NULL
NK-like	NULL
phenotype	NULL
Negative	NULL
RPM	NULL
18932	NULL
EBV	NULL
transformed	NULL
B-cell	NULL
Positive	NULL
PB-697	NULL
Pre-B-ALL	NULL
Positive	NULL
Nalm-6	NULL
Pre-B-ALL	NULL
Positive	NULL
Ramos	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
Positive	NULL
CA-46	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
Positive	NULL
BL41	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
Positive	NULL
Granta	NULL
519	NULL
Mantle	NULL
cell	NULL
lymphoma	NULL
Positive	NULL
NCEB	NULL
1806	NULL
Mantle	NULL
cell	NULL
lymphoma	NULL
Positive	NULL
SU-DHL-4	NULL
Large	NULL
B-cell	NULL
lymphoma	NULL
Positive	NULL
SU-DHL-5	NULL
Large	NULL
B-cell	NULL
lymphoma	NULL
Positive	NULL
SU-DHL-6	NULL
Large	NULL
B-cell	NULL
lymphoma	NULL
Positive	NULL
SU-DHL-10	NULL
Large	NULL
B-cell	NULL
lymphoma	NULL
Positive	NULL
Jim3	NULL
Multiple	NULL
myeloma	NULL
Negative	NULL
KMS11	NULL
Multiple	NULL
myeloma	NULL
Negative	NULL
OPM2	NULL
Multiple	NULL
myeloma	NULL
Negative	NULL
IgM-	NULL
and	NULL
IgD-expressing	NULL
B	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
absence	NULL
of	NULL
BSAP	NULL
in	NULL
immunoblasts	NULL
and	NULL
plasma	NULL
cells	NULL
is	NULL
consistent	NULL
with	NULL
its	NULL
known	NULL
downregulation	NULL
in	NULL
Ig-secreting	NULL
cells	NULL
.	NULL
``	NULL

The	NULL
neoplastic	NULL
B	NULL
cells	NULL
also	NULL
displayed	NULL
varying	NULL
levels	NULL
of	NULL
BSAP	NULL
that	NULL
to	NULL
some	NULL
extent	NULL
paralleled	NULL
the	NULL
levels	NULL
found	NULL
in	NULL
the	NULL
corresponding	NULL
normal	NULL
cells	NULL
.	NULL

Strong	NULL
BSAP	NULL
expression	NULL
was	NULL
observed	NULL
in	NULL
mantle	NULL
cell	NULL
lymphomas	NULL
.	NULL

This	NULL
may	NULL
reflect	NULL
the	NULL
derivation	NULL
of	NULL
this	NULL
lymphoma	NULL
from	NULL
the	NULL
strongly	NULL
positive	NULL
mantle	NULL
zone	NULL
B	NULL
cells	NULL
.	NULL

Whether	NULL
the	NULL
high	NULL
level	NULL
of	NULL
BSAP	NULL
in	NULL
these	NULL
tumors	NULL
contributes	NULL
to	NULL
their	NULL
unfavorable	NULL
clinical	NULL
course	NULL
in	NULL
comparison	NULL
with	NULL
other	NULL
low	NULL
grade	NULL
lymphomas	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

All	NULL
cases	NULL
of	NULL
B-cell	NULL
CLL/SLL	NULL
expressed	NULL
BSAP	NULL
,	NULL
but	NULL
the	NULL
staining	NULL
was	NULL
usually	NULL
less	NULL
intense	NULL
than	NULL
in	NULL
the	NULL
mantle	NULL
cell	NULL
lymphoma	NULL
cases	NULL
.	NULL

Weaker	NULL
immunoreactivity	NULL
of	NULL
prolymphocytes	NULL
and	NULL
paraimmunoblasts	NULL
than	NULL
of	NULL
small	NULL
lymphoma	NULL
cells	NULL
was	NULL
a	NULL
characteristic	NULL
finding	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
BSAP	NULL
immunoreactivity	NULL
even	NULL
spared	NULL
the	NULL
proliferation	NULL
centers	NULL
.	NULL

Because	NULL
prolymphocytes	NULL
and	NULL
paraimmunoblasts	NULL
have	NULL
a	NULL
higher	NULL
proliferative	NULL
activity	NULL
compared	NULL
with	NULL
the	NULL
surrounding	NULL
tumor	NULL
cells	NULL
,	NULL
their	NULL
lower	NULL
BSAP	NULL
levels	NULL
contrasts	NULL
with	NULL
the	NULL
positive	NULL
correlation	NULL
between	NULL
BSAP	NULL
levels	NULL
and	NULL
B-cell	NULL
proliferation	NULL
.	NULL
``	NULL

The	NULL
lowered	NULL
BSAP	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
might	NULL
be	NULL
related	NULL
to	NULL
an	NULL
abortive	NULL
differentiation	NULL
toward	NULL
cells	NULL
with	NULL
increasing	NULL
Ig	NULL
heavy	NULL
chain	NULL
transcription	NULL
.	NULL
``	NULL

All	NULL
but	NULL
1	NULL
(	NULL
95	NULL
%	NULL
)	NULL
of	NULL
the	NULL
21	NULL
follicular	NULL
lymphomas	NULL
were	NULL
Fig	NULL
2	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
Parallel	NULL
sections	NULL
of	NULL
a	NULL
hyperplastic	NULL
lymph	NULL
node	NULL
stained	NULL
for	NULL
BSAP	NULL
and	NULL
CD20	NULL
in	NULL
(	NULL
A	NULL
)	NULL
and	NULL
for	NULL
BSAP	NULL
and	NULL
CD3	NULL
in	NULL
(	NULL
B	NULL
)	NULL
.	NULL

In	NULL
(	NULL
A	NULL
)	NULL
,	NULL
BSAP	NULL
expression	NULL
(	NULL
brow	NULL
n	NULL
nuclear	NULL
staining	NULL
)	NULL
is	NULL
show	NULL
n	NULL
restricted	NULL
to	NULL
the	NULL
CD20	NULL
positive	NULL
B	NULL
cells	NULL
(	NULL
purple-black	NULL
)	NULL
that	NULL
are	NULL
localized	NULL
mainly	NULL
in	NULL
the	NULL
germinal	NULL
center	NULL
and	NULL
mantle	NULL
zone	NULL
(	NULL
lower	NULL
half	NULL
of	NULL
both	NULL
photomicrographs	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
CD3+	NULL
(	NULL
purple-black	NULL
)	NULL
interfollicular	NULL
T	NULL
cells	NULL
in	NULL
(	NULL
B	NULL
)	NULL
are	NULL
essentially	NULL
negative	NULL
for	NULL
BSAP	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
Mantle	NULL
cell	NULL
lymphoma	NULL
stained	NULL
for	NULL
BSAP	NULL
(	NULL
brown	NULL
)	NULL
and	NULL
CD20	NULL
(	NULL
purple-black	NULL
)	NULL
in	NULL
(	NULL
C	NULL
)	NULL
and	NULL
BSAP	NULL
(	NULL
brow	NULL
n	NULL
)	NULL
and	NULL
CD3	NULL
(	NULL
purple-black	NULL
)	NULL
in	NULL
(	NULL
D	NULL
)	NULL
.	NULL

The	NULL
CD20+	NULL
tumor	NULL
cells	NULL
are	NULL
strongly	NULL
positive	NULL
for	NULL
BSAP	NULL
,	NULL
whereas	NULL
the	NULL
CD3+	NULL
T	NULL
cells	NULL
are	NULL
BSAP	NULL
negative	NULL
.	NULL

(	NULL
E	NULL
and	NULL
F	NULL
)	NULL
Mediastinal	NULL
large-cell	NULL
lymphoma	NULL
stained	NULL
for	NULL
BSAP	NULL
and	NULL
CD20	NULL
in	NULL
(	NULL
E	NULL
)	NULL
and	NULL
BSAP	NULL
and	NULL
CD3	NULL
in	NULL
(	NULL
F	NULL
)	NULL
.	NULL

The	NULL
CD20+	NULL
tumor	NULL
cells	NULL
stain	NULL
strongly	NULL
for	NULL
BSAP	NULL
,	NULL
whereas	NULL
the	NULL
nonneoplastic	NULL
infiltrating	NULL
CD3+	NULL
T	NULL
cells	NULL
are	NULL
negative	NULL
for	NULL
BSAP	NULL
(	NULL
G	NULL
)	NULL
FL	NULL
,	NULL
grade	NULL
1	NULL
stained	NULL
for	NULL
BSAP	NULL
(	NULL
brow	NULL
n	NULL
)	NULL
and	NULL
CD3	NULL
(	NULL
purple-black	NULL
)	NULL
.	NULL

Note	NULL
the	NULL
occasional	NULL
CD3+	NULL
,	NULL
BSAP-negative	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
rare	NULL
CD3~	NULL
BSAP-negative	NULL
cells	NULL
that	NULL
most	NULL
likely	NULL
represent	NULL
dendritic	NULL
cells	NULL
.	NULL

(	NULL
H	NULL
)	NULL
AILD-like	NULL
T-cell	NULL
lymphoma	NULL
stained	NULL
for	NULL
BSAP	NULL
(	NULL
brow	NULL
n	NULL
)	NULL
and	NULL
CD20	NULL
(	NULL
purple-black	NULL
)	NULL
.	NULL

The	NULL
tumor	NULL
cells	NULL
are	NULL
negative	NULL
for	NULL
BSAP	NULL
,	NULL
w	NULL
hereas	NULL
2	NULL
residual	NULL
B	NULL
cells	NULL
show	NULL
nuclear	NULL
BSAP	NULL
staining	NULL
and	NULL
membrane	NULL
CD20	NULL
.	NULL

(	NULL
Original	NULL
magnifications	NULL
[	NULL
A	NULL
]	NULL
x400	NULL
,	NULL
[	NULL
B	NULL
]	NULL
x400	NULL
,	NULL
[	NULL
C	NULL
]	NULL
x400	NULL
,	NULL
[	NULL
D	NULL
]	NULL
x400	NULL
,	NULL
[	NULL
E	NULL
]	NULL
1,000	NULL
,	NULL
[	NULL
F	NULL
]	NULL
x1,000	NULL
,	NULL
[	NULL
G	NULL
]	NULL
x	NULL
1,000	NULL
,	NULL
and	NULL
[	NULL
H	NULL
]	NULL
x1,000	NULL
.	NULL
)	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

KRENACS	NULL
ET	NULL
AL	NULL
Fig	NULL
3	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
for	NULL
BSAP	NULL
in	NULL
hematolymphoid	NULL
tumor	NULL
cell	NULL
lines	NULL
.	NULL

(	NULL
A	NULL
)	NULL
YT	NULL
,	NULL
(	NULL
B	NULL
)	NULL
Jurkat	NULL
,	NULL
(	NULL
C	NULL
)	NULL
K562	NULL
,	NULL
(	NULL
D	NULL
)	NULL
PB-697	NULL
,	NULL
(	NULL
E	NULL
)	NULL
Nalm-6	NULL
,	NULL
(	NULL
F	NULL
)	NULL
Ramos	NULL
,	NULL
(	NULL
G	NULL
)	NULL
Granta	NULL
519	NULL
,	NULL
(	NULL
H	NULL
)	NULL
SU-DHL-5	NULL
,	NULL
(	NULL
1	NULL
)	NULL
SU-DHL-6	NULL
,	NULL
and	NULL
(	NULL
J	NULL
)	NULL
NCEB	NULL
1806	NULL
.	NULL

A	NULL
1314	NULL
A	NULL
B	NULL
C	NULL
D	NULL
E	NULL
F	NULL
(	NULL
€	NULL
]	NULL
H	NULL
I	NULL
J	NULL
52	NULL
kDa	NULL
-_-	NULL
®	NULL
@	NULL
B	NULL
an	NULL
--	NULL
-o	NULL
an	NULL
46	NULL
kDa	NULL
omen	NULL
»	NULL
moderately	NULL
to	NULL
strongly	NULL
BSAP	NULL
positive	NULL
.	NULL

In	NULL
many	NULL
cases	NULL
,	NULL
these	NULL
levels	NULL
approximated	NULL
the	NULL
high	NULL
levels	NULL
seen	NULL
in	NULL
normal	NULL
mantle	NULL
cells	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
low	NULL
to	NULL
moderate	NULL
levels	NULL
seen	NULL
in	NULL
their	NULL
corresponding	NULL
nonneoplastic	NULL
counterpart	NULL
,	NULL
reactive	NULL
follicle	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

This	NULL
observation	NULL
suggests	NULL
that	NULL
BSAP	NULL
may	NULL
be	NULL
expressed	NULL
at	NULL
inappropriately	NULL
high	NULL
levels	NULL
in	NULL
some	NULL
FLs	NULL
.	NULL

No	NULL
correlation	NULL
was	NULL
found	NULL
between	NULL
the	NULL
cytological	NULL
grade	NULL
of	NULL
the	NULL
FL	NULL
,	NULL
as	NULL
proposed	NULL
in	NULL
the	NULL
REAL	NULL
Classification	NULL
,	NULL
and	NULL
the	NULL
intensity	NULL
of	NULL
BSAP	NULL
positivity	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
follicular	NULL
lymphoma	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
monocytoid	NULL
B	NULL
cells	NULL
in	NULL
toxoplasma	NULL
lymphadenitis	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
tumor	NULL
cells	NULL
of	NULL
marginal	NULL
zone	NULL
lymphomas	NULL
(	NULL
composed	NULL
of	NULL
monocytoid	NULL
cells	NULL
)	NULL
,	NULL
displayed	NULL
no	NULL
or	NULL
low	NULL
levels	NULL
of	NULL
BSAP	NULL
expression	NULL
.	NULL

Among	NULL
lymphomas	NULL
,	NULL
this	NULL
phenomenon	NULL
was	NULL
most	NULL
apparent	NULL
in	NULL
primary	NULL
monocytoid	NULL
B-cell	NULL
(	NULL
MALT-type	NULL
)	NULL
lymphomas	NULL
of	NULL
the	NULL
parotid	NULL
gland	NULL
.	NULL

Monocytoid	NULL
and	NULL
marginal	NULL
zone	NULL
B	NULL
cells	NULL
are	NULL
considered	NULL
to	NULL
be	NULL
memory	NULL
B	NULL
cells.4*~	NULL
``	NULL
°	NULL
This	NULL
finding	NULL
may	NULL
indicate	NULL
that	NULL
modulation	NULL
of	NULL
BSAP	NULL
expression	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
memory	NULL
B	NULL
cells	NULL
.	NULL

BSAP/PAX-5	NULL
is	NULL
thought	NULL
to	NULL
repress	NULL
Ig	NULL
heavy	NULL
chain	NULL
transcription	NULL
in	NULL
immature	NULL
and	NULL
mature	NULL
B	NULL
cells	NULL
by	NULL
inhibiting	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
3	NULL
'	NULL
a	NULL
chain	NULL
enhancer	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

>	NULL
``	NULL
*	NULL
``	NULL
``	NULL
In	NULL
plasma	NULL
cells	NULL
,	NULL
downregulation	NULL
of	NULL
BSAP	NULL
may	NULL
remove	NULL
this	NULL
repressive	NULL
activity	NULL
on	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
3	NULL
'	NULL
enhancer	NULL
,	NULL
facilitating	NULL
high	NULL
levels	NULL
of	NULL
Ig	NULL
heavy	NULL
chain	NULL
transcription	NULL
.	NULL

Because	NULL
the	NULL
BSAP	NULL
antibodies	NULL
failed	NULL
to	NULL
react	NULL
in	NULL
decalcified	NULL
bone	NULL
marrow	NULL
core	NULL
biopsies	NULL
,	NULL
we	NULL
could	NULL
study	NULL
only	NULL
a	NULL
limited	NULL
number	NULL
of	NULL
plasmacytoma/	NULL
myeloma	NULL
cases	NULL
.	NULL

We	NULL
did	NULL
not	NULL
find	NULL
nuclear	NULL
BSAP	NULL
expression	NULL
in	NULL
either	NULL
normal	NULL
or	NULL
neoplastic	NULL
plasma	NULL
cells	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
results	NULL
,	NULL
a	NULL
recent	NULL
study	NULL
on	NULL
PAX-5	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
myeloma	NULL
cells	NULL
also	NULL
reported	NULL
the	NULL
failure	NULL
to	NULL
detect	NULL
PAX-5	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
.	NULL
``	NULL

A	NULL
substantial	NULL
fraction	NULL
(	NULL
5/24	NULL
[	NULL
21	NULL
%	NULL
]	NULL
)	NULL
of	NULL
the	NULL
LBCL	NULL
cases	NULL
was	NULL
negative	NULL
for	NULL
BSAP	NULL
.	NULL

Most	NULL
LBCLs	NULL
are	NULL
thought	NULL
to	NULL
arise	NULL
from	NULL
peripheral	NULL
antigen	NULL
stimulated	NULL
B	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
the	NULL
clinical	NULL
,	NULL
pathological	NULL
,	NULL
and	NULL
molecular	NULL
heterogeneity	NULL
of	NULL
these	NULL
lymphomas	NULL
suggests	NULL
their	NULL
derivation	NULL
from	NULL
B	NULL
cells	NULL
of	NULL
various	NULL
stages	NULL
of	NULL
differentiation	NULL
,	NULL
and	NULL
this	NULL
heterogeneity	NULL
was	NULL
reflected	NULL
in	NULL
their	NULL
BSAP	NULL
expression	NULL
.	NULL

The	NULL
BSAP-negative	NULL
LBCL	NULL
cases	NULL
might	NULL
be	NULL
derived	NULL
from	NULL
postfollicular	NULL
transformed	NULL
B	NULL
cells	NULL
representing	NULL
the	NULL
transition	NULL
from	NULL
mature	NULL
B	NULL
cells	NULL
to	NULL
plasma	NULL
cells	NULL
.	NULL

Almost	NULL
half	NULL
(	NULL
10/24	NULL
[	NULL
42	NULL
%	NULL
]	NULL
)	NULL
of	NULL
the	NULL
LBCL	NULL
cases	NULL
,	NULL
including	NULL
all	NULL
3	NULL
mediastinal	NULL
LBCL	NULL
cases	NULL
tested	NULL
,	NULL
displayed	NULL
strong	NULL
BSAP	NULL
positivity	NULL
.	NULL

The	NULL
strong	NULL
BSAP	NULL
expression	NULL
may	NULL
be	NULL
part	NULL
of	NULL
their	NULL
malignant	NULL
phenotype	NULL
,	NULL
representing	NULL
overexpression	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
low	NULL
surface	NULL
Ig	NULL
expression	NULL
characteristic	NULL
of	NULL
mediastinal	NULL
LBCLs*®	NULL
may	NULL
be	NULL
related	NULL
to	NULL
their	NULL
high-level	NULL
expression	NULL
of	NULL
BSAP	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
Ig	NULL
repressor	NULL
function	NULL
of	NULL
BSAP	NULL
.	NULL

Whether	NULL
the	NULL
variable	NULL
expression	NULL
level	NULL
of	NULL
BSAP	NULL
in	NULL
LBCLs	NULL
defines	NULL
clinically	NULL
relevant	NULL
subgroups	NULL
remains	NULL
to	NULL
be	NULL
tested	NULL
.	NULL

52-kD	NULL
band	NULL
of	NULL
expected	NULL
size	NULL
is	NULL
demonstrated	NULL
only	NULL
in	NULL
the	NULL
B-cell	NULL
lines	NULL
(	NULL
D	NULL
through	NULL
J	NULL
)	NULL
.	NULL

PB-697	NULL
and	NULL
Nalm-6	NULL
also	NULL
display	NULL
a	NULL
second	NULL
band	NULL
of	NULL
46	NULL
kD	NULL
,	NULL
which	NULL
has	NULL
a	NULL
much	NULL
lower	NULL
intensity	NULL
in	NULL
Nalm-6	NULL
.	NULL

This	NULL
band	NULL
originates	NULL
from	NULL
a	NULL
cytoplasmic	NULL
cross-reactive	NULL
protein	NULL
that	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
related	NULL
to	NULL
BSAP	NULL
(	NULL
see	NULL
text	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
LPHD	NULL
,	NULL
which	NULL
is	NULL
generally	NULL
accepted	NULL
to	NULL
be	NULL
a	NULL
B-cell	NULL
process	NULL
,	NULL
``	NULL
``	NULL
weak	NULL
BSAP	NULL
expression	NULL
was	NULL
also	NULL
found	NULL
in	NULL
38	NULL
%	NULL
(	NULL
6/16	NULL
)	NULL
classical	NULL
HD	NULL
cases	NULL
.	NULL

Our	NULL
result	NULL
is	NULL
contrary	NULL
to	NULL
the	NULL
findings	NULL
in	NULL
the	NULL
HRS	NULL
cell	NULL
lines	NULL
,	NULL
L428	NULL
,	NULL
HDLM-1	NULL
,	NULL
and	NULL
KM-H2	NULL
,	NULL
in	NULL
which	NULL
BSAP	NULL
was	NULL
not	NULL
detected	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL
``	NULL

The	NULL
weak	NULL
BSAP	NULL
expression	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
developing	NULL
consensus	NULL
of	NULL
a	NULL
B-cell	NULL
derivation	NULL
for	NULL
classical	NULL
HD	NULL
in	NULL
a	NULL
high	NULL
proportion	NULL
of	NULL
cases	NULL
.	NULL
``	NULL

''	NULL
The	NULL
nonrandom	NULL
chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
9	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
;	NULL
q32	NULL
)	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
cases	NULL
of	NULL
the	NULL
lymphoplasmacytoid	NULL
lymphoma	NULL
subtype	NULL
of	NULL
NHL	NULL
.	NULL

*	NULL
``	NULL
This	NULL
translocation	NULL
was	NULL
recently	NULL
cloned	NULL
and	NULL
shown	NULL
to	NULL
result	NULL
in	NULL
the	NULL
juxtaposition	NULL
of	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
Sy	NULL
region	NULL
to	NULL
the	NULL
9p13	NULL
locus	NULL
,	NULL
``	NULL
**	NULL
``	NULL
in	NULL
which	NULL
the	NULL
PAX-5	NULL
gene	NULL
has	NULL
been	NULL
mapped	NULL
,	NULL
``	NULL
%	NULL
``	NULL
5	NULL
leading	NULL
to	NULL
overexpression	NULL
of	NULL
the	NULL
PAX-5	NULL
gene	NULL
product	NULL
.	NULL
``	NULL

This	NULL
is	NULL
further	NULL
evidence	NULL
that	NULL
BSAP/PAX-5	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
some	NULL
B-cell	NULL
lymphomas	NULL
.	NULL

Lymphoplasmacytoid	NULL
lymphomas	NULL
are	NULL
relatively	NULL
rare	NULL
;	NULL
in	NULL
the	NULL
current	NULL
study	NULL
,	NULL
none	NULL
was	NULL
included	NULL
.	NULL

B-cell-restricted	NULL
expression	NULL
of	NULL
BSAP	NULL
was	NULL
also	NULL
confirmed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

BSAP	NULL
was	NULL
detected	NULL
in	NULL
cell	NULL
lines	NULL
corresponding	NULL
to	NULL
precursor	NULL
and	NULL
mature	NULL
B-cell	NULL
stages	NULL
,	NULL
but	NULL
not	NULL
in	NULL
terminally	NULL
differentiated	NULL
plasma	NULL
cell	NULL
,	NULL
T-cell	NULL
,	NULL
or	NULL
other	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
2	NULL
and	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
52-kD	NULL
band	NULL
known	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
BSAP	NULL
,	NULL
a	NULL
46-kD	NULL
band	NULL
was	NULL
also	NULL
found	NULL
in	NULL
the	NULL
lysate	NULL
of	NULL
the	NULL
PB-697	NULL
cell	NULL
line	NULL
,	NULL
a	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
pre-B	NULL
ALL	NULL
.	NULL

A	NULL
similar	NULL
,	NULL
although	NULL
less	NULL
prominent	NULL
band	NULL
was	NULL
also	NULL
found	NULL
in	NULL
lysates	NULL
from	NULL
the	NULL
pre-B-cell	NULL
line	NULL
Nalm-6	NULL
.	NULL

Because	NULL
we	NULL
detected	NULL
the	NULL
46-kD	NULL
band	NULL
only	NULL
with	NULL
the	NULL
N-terminal	NULL
BSAP-specific	NULL
antiserum	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
to	NULL
differ	NULL
from	NULL
the	NULL
52-kD	NULL
form	NULL
of	NULL
BSAP	NULL
at	NULL
the	NULL
carboxy-terminus	NULL
.	NULL

Distinct	NULL
Pax-5	NULL
isoforms	NULL
generated	NULL
by	NULL
alternative	NULL
splicing	NULL
have	NULL
been	NULL
described	NULL
in	NULL
murine	NULL
neural	NULL
,	NULL
B-lymphoid	NULL
,	NULL
and	NULL
testicular	NULL
tissues	NULL
.	NULL
``	NULL

Although	NULL
we	NULL
initially	NULL
though	NULL
that	NULL
the	NULL
46-kD	NULL
band	NULL
represented	NULL
a	NULL
distinct	NULL
BSAP	NULL
isoform	NULL
,	NULL
further	NULL
analysis	NULL
has	NULL
suggested	NULL
that	NULL
it	NULL
represents	NULL
a	NULL
cross-reactive	NULL
band	NULL
present	NULL
in	NULL
the	NULL
two	NULL
pre-B-cell	NULL
lines	NULL
.	NULL

In	NULL
nonhematopoietic	NULL
tumors	NULL
,	NULL
PAX	NULL
gene	NULL
products	NULL
acquire	NULL
their	NULL
oncogenic	NULL
activity	NULL
through	NULL
inappropriate	NULL
expression	NULL
and/or	NULL
gain-of-function	NULL
alterations	NULL
.	NULL

The	NULL
strong	NULL
expression	NULL
of	NULL
PAX-5	NULL
found	NULL
in	NULL
B-cell	NULL
lymphomas	NULL
may	NULL
possibly	NULL
indicate	NULL
a	NULL
role	NULL
for	NULL
this	NULL
paired	NULL
box	NULL
protein	NULL
in	NULL
some	NULL
lymphomas	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
because	NULL
BSAP	NULL
is	NULL
strongly	NULL
expressed	NULL
normally	NULL
during	NULL
some	NULL
stages	NULL
of	NULL
normal	NULL
B-cell	NULL
differentiation	NULL
(	NULL
eg	NULL
,	NULL
mantle	NULL
cells	NULL
)	NULL
,	NULL
we	NULL
can	NULL
only	NULL
infer	NULL
involvement	NULL
of	NULL
BSAP	NULL
in	NULL
those	NULL
lymphomas	NULL
for	NULL
which	NULL
the	NULL
intensity	NULL
of	NULL
expression	NULL
exceeded	NULL
the	NULL
expression	NULL
level	NULL
of	NULL
the	NULL
putative	NULL
normal	NULL
cellular	NULL
counterpart	NULL
(	NULL
deregulated	NULL
expression	NULL
)	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
the	NULL
strong	NULL
BSAP	NULL
expression	NULL
in	NULL
LBCL	NULL
(	NULL
especially	NULL
the	NULL
mediastinal	NULL
large	NULL
B-cell	NULL
lymphomas	NULL
)	NULL
and	NULL
some	NULL
FLs	NULL
can	NULL
be	NULL
considered	NULL
to	NULL
be	NULL
particularly	NULL
interesting	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
BSAP	NULL
expression	NULL
is	NULL
unique	NULL
to	NULL
the	NULL
B-cell	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BSAP	NULL
EXPRESSION	NULL
IN	NULL
LYMPHOID	NULL
MALIGNANCIES	NULL
lineage	NULL
among	NULL
hematopoietic	NULL
cells	NULL
and	NULL
tumors	NULL
.	NULL

Double-staining	NULL
studies	NULL
demonstrated	NULL
that	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
BSAP-positive	NULL
cells	NULL
coexpress	NULL
CD20	NULL
and	NULL
that	NULL
few	NULL
,	NULL
if	NULL
any	NULL
,	NULL
express	NULL
CD3	NULL
.	NULL

BSAP	NULL
levels	NULL
vary	NULL
among	NULL
B-cell	NULL
subsets	NULL
and	NULL
among	NULL
subtypes	NULL
of	NULL
B-cell	NULL
lymphoma	NULL
,	NULL
with	NULL
the	NULL
highest	NULL
levels	NULL
detected	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
mantle	NULL
cells	NULL
,	NULL
in	NULL
some	NULL
FLs	NULL
,	NULL
and	NULL
in	NULL
a	NULL
proportion	NULL
of	NULL
LBCL	NULL
,	NULL
including	NULL
all	NULL
mediastinal	NULL
large	NULL
B-cell	NULL
lymphomas	NULL
stud-ied	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
weak	NULL
BSAP	NULL
expression	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
about	NULL
one	NULL
third	NULL
of	NULL
all	NULL
classical	NULL
HD	NULL
cases	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
the	NULL
high	NULL
levels	NULL
of	NULL
BSAP	NULL
,	NULL
particularly	NULL
those	NULL
found	NULL
in	NULL
LBCL	NULL
,	NULL
and	NULL
in	NULL
some	NULL
cases	NULL
of	NULL
FLs	NULL
,	NULL
may	NULL
be	NULL
a	NULL
result	NULL
of	NULL
deregulated	NULL
BSAP/PAX-5	NULL
expression	NULL
,	NULL
suggesting	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
PAX-5	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
some	NULL
B-cell	NULL
malignancies	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
are	NULL
grateful	NULL
to	NULL
Alan	NULL
Epstein	NULL
for	NULL
providing	NULL
SU-DHL-1	NULL
,	NULL
-4	NULL
,	NULL
-5	NULL
,	NULL
and	NULL
-10	NULL
cell	NULL
lines	NULL
;	NULL
to	NULL
Michael	NULL
Kuehl	NULL
for	NULL
Jim3	NULL
,	NULL
KMS11	NULL
,	NULL
and	NULL
OPM2	NULL
;	NULL
to	NULL
Ian	NULL
Magrath	NULL
for	NULL
CA-46	NULL
and	NULL
BL41	NULL
;	NULL
to	NULL
Thomas	NULL
Tedder	NULL
for	NULL
PB-697	NULL
and	NULL
Nalm-6	NULL
;	NULL
to	NULL
A.	NULL
Karpas	NULL
for	NULL
Karpas	NULL
299	NULL
;	NULL
to	NULL
Junji	NULL
Yodoi	NULL
for	NULL
YT	NULL
;	NULL
to	NULL
Takemi	NULL
Otsuki	NULL
for	NULL
NCEB	NULL
1806	NULL
;	NULL
and	NULL
to	NULL
Martin	NULL
Dyer	NULL
for	NULL
the	NULL
Granta	NULL
519	NULL
cell	NULL
line	NULL
.	NULL

Cell	NULL
lines	NULL
not	NULL
mentioned	NULL
above	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Cell	NULL
Culture	NULL
(	NULL
ATCC	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Cynthia	NULL
A.	NULL
Harris	NULL
and	NULL
Sarah	NULL
E.	NULL
Delay-Brown	NULL
for	NULL
their	NULL
expert	NULL
technical	NULL
assistance	NULL
and	NULL
Ralph	NULL
L.	NULL
Isenberg	NULL
for	NULL
his	NULL
photographic	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Barberis	NULL
A	NULL
,	NULL
Widenhorn	NULL
K	NULL
,	NULL
Vitelli	NULL
L	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
A	NULL
novel	NULL
B-cell	NULL
lineage-specific	NULL
transcription	NULL
factor	NULL
present	NULL
at	NULL
early	NULL
but	NULL
not	NULL
late	NULL
stages	NULL
of	NULL
differentiation	NULL
.	NULL

Genes	NULL
Dev	NULL
4:849	NULL
,	NULL
1990	NULL
2	NULL
.	NULL

Adams	NULL
B	NULL
,	NULL
Dorfler	NULL
P	NULL
,	NULL
Aguzzi	NULL
A	NULL
,	NULL
Kozmik	NULL
Z	NULL
,	NULL
Urbanek	NULL
P	NULL
,	NULL
Maurer-Fogy	NULL
I	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
Pax-5	NULL
encodes	NULL
the	NULL
transcription	NULL
factor	NULL
BSAP	NULL
and	NULL
is	NULL
expressed	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
the	NULL
developing	NULL
CNS	NULL
,	NULL
and	NULL
adult	NULL
testis	NULL
.	NULL

Genes	NULL
Dev	NULL
6:1589	NULL
,	NULL
1992	NULL
3	NULL
.	NULL

Singh	NULL
M	NULL
,	NULL
Birshtein	NULL
BK	NULL
:	NULL
NE-HB	NULL
(	NULL
BSAP	NULL
)	NULL
is	NULL
a	NULL
repressor	NULL
of	NULL
the	NULL
murine	NULL
immunoglobulin	NULL
heavy-chain	NULL
3	NULL
'	NULL
alpha	NULL
enhancer	NULL
at	NULL
early	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:3611	NULL
,	NULL
1993	NULL
4	NULL
.	NULL

Waters	NULL
SH	NULL
,	NULL
Saikh	NULL
KU	NULL
,	NULL
Stavnezer	NULL
E	NULL
:	NULL
A	NULL
B-cell-specific	NULL
nuclear	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
DNA	NULL
sites	NULL
5	NULL
'	NULL
to	NULL
immunoglobulin	NULL
Sa	NULL
tandem	NULL
repeats	NULL
is	NULL
regulated	NULL
during	NULL
differentiation	NULL
.	NULL

J	NULL
Mol	NULL
Cell	NULL
Biol	NULL
9:5594	NULL
,	NULL
1989	NULL
5	NULL
.	NULL

Xu	NULL
L	NULL
,	NULL
Kim	NULL
MG	NULL
,	NULL
Marcu	NULL
KB	NULL
:	NULL
Properties	NULL
of	NULL
B	NULL
cell	NULL
stage	NULL
specific	NULL
and	NULL
ubiquitous	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
gene	NULL
switch	NULL
regions	NULL
.	NULL

Int	NULL
Immunol	NULL
4:875	NULL
,	NULL
1992	NULL
6	NULL
.	NULL

Williams	NULL
M	NULL
,	NULL
Maizels	NULL
N	NULL
:	NULL
LR1	NULL
,	NULL
a	NULL
lipopolysaccharide-responsive	NULL
factor	NULL
with	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
immunoglobulin	NULL
switch	NULL
regions	NULL
and	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Genes	NULL
Dev	NULL
5:2353	NULL
,	NULL
1991	NULL
7	NULL
.	NULL

Okabe	NULL
T	NULL
,	NULL
Bauer	NULL
SB	NULL
,	NULL
Kudo	NULL
A	NULL
:	NULL
A	NULL
pre-B-	NULL
and	NULL
B-cell-specific	NULL
DNA	NULL
binding	NULL
protein	NULL
,	NULL
EBB-1	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
VpreB1	NULL
gene	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
22:31	NULL
,	NULL
1992	NULL
8	NULL
.	NULL

Busslinger	NULL
M	NULL
,	NULL
Urbdnek	NULL
P	NULL
:	NULL
The	NULL
role	NULL
of	NULL
BSAP	NULL
(	NULL
Pax-5	NULL
)	NULL
in	NULL
B-cell	NULL
development	NULL
.	NULL

Curr	NULL
Opin	NULL
Genet	NULL
Dev	NULL
5:595	NULL
,	NULL
1995	NULL
9	NULL
.	NULL

Max	NULL
EE	NULL
,	NULL
Wakatsuki	NULL
Y	NULL
,	NULL
Neurath	NULL
MF	NULL
,	NULL
Strober	NULL
W	NULL
:	NULL
The	NULL
role	NULL
of	NULL
BSAP	NULL
in	NULL
immunoglobulin	NULL
isotype	NULL
switching	NULL
and	NULL
B-cell	NULL
proliferation	NULL
.	NULL

Curr	NULL
Top	NULL
Microbiol	NULL
Immunol	NULL
194:449	NULL
,	NULL
1995	NULL
10	NULL
.	NULL

Kozmik	NULL
Z	NULL
,	NULL
Wang	NULL
S	NULL
,	NULL
Dérfler	NULL
P	NULL
,	NULL
Adams	NULL
B	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
The	NULL
promoter	NULL
of	NULL
the	NULL
CD19	NULL
gene	NULL
is	NULL
a	NULL
target	NULL
for	NULL
the	NULL
B-cell-specific	NULL
transcription	NULL
factor	NULL
BSAP	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:2662	NULL
,	NULL
1992	NULL
11	NULL
.	NULL

Wakatsuki	NULL
Y	NULL
,	NULL
Nuerath	NULL
MF	NULL
,	NULL
Max	NULL
EE	NULL
,	NULL
Strober	NULL
W	NULL
:	NULL
The	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
BSAP	NULL
regulates	NULL
B	NULL
cell	NULL
proliferation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
179:1099	NULL
,	NULL
1994	NULL
12	NULL
.	NULL

Kehrl	NULL
JH	NULL
,	NULL
Riva	NULL
A	NULL
,	NULL
Wilson	NULL
GL	NULL
,	NULL
Thevenin	NULL
C	NULL
:	NULL
Molecular	NULL
mechanisms	NULL
regulating	NULL
CD19	NULL
,	NULL
CD20	NULL
and	NULL
CD22	NULL
gene	NULL
expression	NULL
.	NULL

Immunol	NULL
Today	NULL
15:432	NULL
,	NULL
1994	NULL
13	NULL
.	NULL

Urbanek	NULL
P	NULL
,	NULL
Wang	NULL
Z-Q	NULL
,	NULL
Fetka	NULL
I	NULL
,	NULL
Wagner	NULL
EF	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
1315	NULL
Complete	NULL
block	NULL
of	NULL
early	NULL
B	NULL
cell	NULL
differentiation	NULL
and	NULL
altered	NULL
patterning	NULL
of	NULL
the	NULL
posterior	NULL
midbrain	NULL
in	NULL
mice	NULL
lacking	NULL
Pax	NULL
5/BSAP	NULL
.	NULL

Cell	NULL
79:901	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Neurath	NULL
MF	NULL
,	NULL
Strober	NULL
W	NULL
,	NULL
Wakatsuk	NULL
Y	NULL
:	NULL
The	NULL
murine	NULL
Ig	NULL
3	NULL
'	NULL
a	NULL
enhancer	NULL
is	NULL
a	NULL
target	NULL
site	NULL
with	NULL
repressor	NULL
function	NULL
for	NULL
the	NULL
B-cell	NULL
lineage-specific	NULL
transcription	NULL
factor	NULL
BSAP	NULL
(	NULL
NF-HB	NULL
,	NULL
S-BP	NULL
)	NULL
.	NULL

J	NULL
Immunol	NULL
153:730	NULL
,	NULL
1994	NULL
15	NULL
.	NULL

Neurath	NULL
MF	NULL
,	NULL
Max	NULL
EE	NULL
,	NULL
Strober	NULL
W	NULL
:	NULL
Pax5	NULL
(	NULL
BSAP	NULL
)	NULL
regulates	NULL
the	NULL
murine	NULL
immunoglobulin	NULL
3	NULL
'	NULL
alpha	NULL
enhancer	NULL
by	NULL
suppressing	NULL
binding	NULL
of	NULL
NF-alpha	NULL
P	NULL
,	NULL
a	NULL
protein	NULL
that	NULL
controls	NULL
heavy	NULL
chain	NULL
transcription	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:5336	NULL
,	NULL
1995	NULL
16	NULL
.	NULL

Chalepakis	NULL
G	NULL
,	NULL
Fritsch	NULL
R	NULL
,	NULL
Fickenscher	NULL
H	NULL
,	NULL
Deutsch	NULL
U	NULL
,	NULL
Goulding	NULL
M	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
The	NULL
molecular	NULL
basis	NULL
of	NULL
the	NULL
undulated/Pax-1	NULL
mutation	NULL
.	NULL

Cell	NULL
66:873	NULL
,	NULL
1991	NULL
17	NULL
.	NULL

Walther	NULL
C	NULL
,	NULL
Guenet	NULL
J-L	NULL
,	NULL
Simon	NULL
D	NULL
,	NULL
Deutsch	NULL
U	NULL
,	NULL
Jostes	NULL
B	NULL
,	NULL
Goulding	NULL
M	NULL
,	NULL
Plachov	NULL
D	NULL
,	NULL
Balling	NULL
R	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
Pax	NULL
:	NULL
A	NULL
murine	NULL
multigene	NULL
family	NULL
of	NULL
paired	NULL
box	NULL
containing	NULL
genes	NULL
.	NULL

Genomics	NULL
11:424	NULL
,	NULL
1991	NULL
18	NULL
.	NULL

Stapleton	NULL
P	NULL
,	NULL
Weith	NULL
A	NULL
,	NULL
Urbanek	NULL
P	NULL
,	NULL
Kozmik	NULL
Z	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
Chromosomal	NULL
localization	NULL
of	NULL
seven	NULL
PAX	NULL
genes	NULL
and	NULL
cloning	NULL
of	NULL
a	NULL
novel	NULL
family	NULL
member	NULL
,	NULL
PAX-9	NULL
.	NULL

Nat	NULL
Genet	NULL
3:292	NULL
,	NULL
1993	NULL
19	NULL
.	NULL

Chalepakis	NULL
G	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
Identification	NULL
of	NULL
DNA	NULL
recognition	NULL
sequences	NULL
for	NULL
the	NULL
Pax3	NULL
paired	NULL
domain	NULL
.	NULL

Gene	NULL
162:267	NULL
,	NULL
1995	NULL
20	NULL
.	NULL

Chalepakis	NULL
G	NULL
,	NULL
Stoykova	NULL
A	NULL
,	NULL
Wijnholds	NULL
J	NULL
,	NULL
Tremblay	NULL
P	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
Pax	NULL
:	NULL
Gene	NULL
regulators	NULL
in	NULL
the	NULL
developing	NULL
nervous	NULL
system	NULL
.	NULL

J	NULL
Neurobiol	NULL
2411367	NULL
,	NULL
1993	NULL
21	NULL
.	NULL

Strachan	NULL
T	NULL
,	NULL
Read	NULL
AP	NULL
:	NULL
PAX	NULL
genes	NULL
.	NULL

Curr	NULL
Opin	NULL
Genet	NULL
Dev	NULL
4:427	NULL
,	NULL
1994	NULL
22	NULL
.	NULL

Gerard	NULL
M	NULL
,	NULL
Abitbol	NULL
M	NULL
,	NULL
Delezoide	NULL
AL	NULL
,	NULL
Dufier	NULL
JL	NULL
,	NULL
Mallet	NULL
J	NULL
,	NULL
Vekemans	NULL
M	NULL
:	NULL
PAX-genes	NULL
expression	NULL
during	NULL
human	NULL
embryonic	NULL
development	NULL
,	NULL
a	NULL
preliminary	NULL
report	NULL
.	NULL

C	NULL
R	NULL
Acad	NULL
Sci	NULL
III	NULL
318:57	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

Maulbecker	NULL
CC	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
The	NULL
oncogenic	NULL
potential	NULL
of	NULL
Pax	NULL
genes	NULL
.	NULL

EMBO	NULL
J	NULL
12:2361	NULL
,	NULL
1993	NULL
24	NULL
.	NULL

Poleey	NULL
A	NULL
,	NULL
Fickenscher	NULL
H	NULL
,	NULL
Mundlos	NULL
S	NULL
,	NULL
Winterpacht	NULL
A	NULL
,	NULL
Zabel	NULL
B	NULL
,	NULL
Fidler	NULL
A	NULL
,	NULL
Gruss	NULL
P	NULL
,	NULL
Plachov	NULL
D	NULL
:	NULL
PAX8	NULL
,	NULL
a	NULL
human	NULL
paired	NULL
box	NULL
gene	NULL
:	NULL
isolation	NULL
and	NULL
expression	NULL
in	NULL
developing	NULL
thyroid	NULL
,	NULL
kidney	NULL
and	NULL
Wilms	NULL
'	NULL
tumors	NULL
.	NULL

Development	NULL
116:611	NULL
,	NULL
1992	NULL
25	NULL
.	NULL

Dressler	NULL
GR	NULL
,	NULL
Douglass	NULL
EC	NULL
:	NULL
Pax2	NULL
is	NULL
an	NULL
DNA-binding	NULL
protein	NULL
expressed	NULL
in	NULL
embryonic	NULL
kidney	NULL
and	NULL
Wilms'tumor	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:1179	NULL
,	NULL
1992	NULL
26	NULL
.	NULL

Barr	NULL
FG	NULL
,	NULL
Galili	NULL
N	NULL
,	NULL
Holick	NULL
J	NULL
,	NULL
Biegel	NULL
JA	NULL
,	NULL
Rovera	NULL
G	NULL
,	NULL
Emanuel	NULL
BS	NULL
:	NULL
Rearrangement	NULL
of	NULL
the	NULL
PAX3	NULL
paired	NULL
box	NULL
gene	NULL
in	NULL
the	NULL
paediatric	NULL
solid	NULL
tumour	NULL
alveolar	NULL
rhabdomyosarcoma	NULL
.	NULL

Nat	NULL
Genet	NULL
3:113	NULL
,	NULL
1993	NULL
27	NULL
.	NULL

Davis	NULL
RJ	NULL
,	NULL
D'Cruz	NULL
CM	NULL
,	NULL
Lovell	NULL
MA	NULL
,	NULL
Biegel	NULL
JA	NULL
,	NULL
Barr	NULL
FG	NULL
:	NULL
Fusion	NULL
of	NULL
PAX7	NULL
to	NULL
FKHR	NULL
by	NULL
the	NULL
variant	NULL
t	NULL
(	NULL
1	NULL
;	NULL
13	NULL
)	NULL
(	NULL
p36	NULL
;	NULL
q14	NULL
)	NULL
translocation	NULL
in	NULL
alveolar	NULL
rhabdomyosarcoma	NULL
.	NULL

Cancer	NULL
Res	NULL
54:2869	NULL
,	NULL
1994	NULL
28	NULL
.	NULL

Davis	NULL
RJ	NULL
,	NULL
Bennicelli	NULL
JL	NULL
,	NULL
Macina	NULL
RA	NULL
,	NULL
Nycum	NULL
LM	NULL
,	NULL
Biegel	NULL
JA	NULL
,	NULL
Barr	NULL
FG	NULL
:	NULL
Structural	NULL
characterization	NULL
of	NULL
the	NULL
FKHR	NULL
gene	NULL
and	NULL
its	NULL
rearrangement	NULL
in	NULL
alveolar	NULL
rhabdomyosarcoma	NULL
.	NULL

Hum	NULL
Mol	NULL
Genet	NULL
4:2355	NULL
,	NULL
1995	NULL
29	NULL
.	NULL

Gnarra	NULL
JR	NULL
,	NULL
Dressler	NULL
GR	NULL
:	NULL
Expression	NULL
of	NULL
Pax-2	NULL
in	NULL
human	NULL
renal	NULL
cell	NULL
carcinoma	NULL
and	NULL
growth	NULL
inhibition	NULL
by	NULL
antisense	NULL
oligonucleotides	NULL
.	NULL

Cancer	NULL
Res	NULL
55:4092	NULL
,	NULL
1995	NULL
30	NULL
.	NULL

Bennicelli	NULL
JL	NULL
,	NULL
Edwards	NULL
RH	NULL
,	NULL
Barr	NULL
FG	NULL
:	NULL
Mechanism	NULL
for	NULL
transcrip-tional	NULL
gain	NULL
of	NULL
function	NULL
resulting	NULL
from	NULL
chromosomal	NULL
translocation	NULL
in	NULL
alveolar	NULL
rhabdomyosarcoma	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:5455	NULL
,	NULL
1996	NULL
31	NULL
.	NULL

Kozmik	NULL
Z	NULL
,	NULL
Sure	NULL
U	NULL
,	NULL
Ruedi	NULL
D	NULL
,	NULL
Busslinger	NULL
M	NULL
,	NULL
Aguzzi	NULL
A	NULL
:	NULL
Deregulated	NULL
expression	NULL
of	NULL
PAXS5	NULL
in	NULL
medulloblastoma	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:5709	NULL
,	NULL
1995	NULL
32	NULL
.	NULL

Stuart	NULL
ET	NULL
,	NULL
Kioussi	NULL
C	NULL
,	NULL
Aguzzi	NULL
A	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
PaxS5	NULL
expression	NULL
correlates	NULL
with	NULL
increasing	NULL
malignancy	NULL
in	NULL
human	NULL
astrocytomas	NULL
.	NULL

Clin	NULL
Cancer	NULL
Res	NULL
1:207	NULL
,	NULL
1995	NULL
33	NULL
.	NULL

Stuart	NULL
ET	NULL
,	NULL
Haffner	NULL
R	NULL
,	NULL
Oren	NULL
M	NULL
,	NULL
Gruss	NULL
P	NULL
:	NULL
Loss	NULL
of	NULL
p53	NULL
function	NULL
trough	NULL
PAX-mediated	NULL
transcriptionan	NULL
repression	NULL
.	NULL

EMBO	NULL
J	NULL
14:5638	NULL
,	NULL
1995	NULL
34.	NULL
lida	NULL
S	NULL
,	NULL
Rao	NULL
PH	NULL
,	NULL
Nallasivam	NULL
P	NULL
,	NULL
Hibshoosh	NULL
H	NULL
,	NULL
Butler	NULL
M	NULL
,	NULL
Louie	NULL
DC	NULL
,	NULL
Dyomin	NULL
V	NULL
,	NULL
Ohno	NULL
H	NULL
,	NULL
Chaganti	NULL
RSK	NULL
,	NULL
Dalla-Favara	NULL
R	NULL
:	NULL
The	NULL
t	NULL
(	NULL
9	NULL
;	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1316	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
;	NULL
q32	NULL
)	NULL
chromosomal	NULL
translocation	NULL
associated	NULL
with	NULL
lymphoplas-mocytoid	NULL
lymphoma	NULL
involves	NULL
the	NULL
PAX-5	NULL
gene	NULL
.	NULL

Blood	NULL
88:4110	NULL
,	NULL
1996	NULL
35	NULL
.	NULL

Harris	NULL
NL	NULL
,	NULL
Jaffe	NULL
ES	NULL
,	NULL
Stein	NULL
H	NULL
,	NULL
Banks	NULL
PM	NULL
,	NULL
Chan	NULL
JKC	NULL
,	NULL
Cleary	NULL
ML	NULL
,	NULL
Delsol	NULL
G	NULL
,	NULL
De	NULL
Wolf-Peters	NULL
C	NULL
,	NULL
Falini	NULL
B	NULL
,	NULL
Gatter	NULL
KC	NULL
,	NULL
Grogan	NULL
TM	NULL
,	NULL
Isaacson	NULL
PG	NULL
,	NULL
Knowles	NULL
TM	NULL
,	NULL
Mason	NULL
DY	NULL
,	NULL
Muller-Hermelink	NULL
H-K	NULL
,	NULL
Pileri	NULL
SA	NULL
,	NULL
Piris	NULL
MA	NULL
,	NULL
Ralfkiaer	NULL
E	NULL
,	NULL
Warnke	NULL
RA	NULL
:	NULL
A	NULL
revised	NULL
European-American	NULL
classification	NULL
of	NULL
lymphoid	NULL
neoplasms	NULL
:	NULL
A	NULL
proposal	NULL
from	NULL
the	NULL
International	NULL
Lymphoma	NULL
Study	NULL
Group	NULL
.	NULL

Blood	NULL
84:1361	NULL
,	NULL
1994	NULL
36	NULL
.	NULL

Krenacs	NULL
L	NULL
,	NULL
Harris	NULL
CA	NULL
,	NULL
Raffeld	NULL
M	NULL
,	NULL
Jaffe	NULL
ES	NULL
:	NULL
Immunohistochemical	NULL
diagnosis	NULL
of	NULL
T-cell	NULL
lymphomas	NULL
in	NULL
paraffin	NULL
sections	NULL
.	NULL

J	NULL
Cell	NULL
Pathol	NULL
1:125	NULL
,	NULL
1996	NULL
37	NULL
.	NULL

Krenacs	NULL
L	NULL
,	NULL
Wellmann	NULL
A	NULL
,	NULL
Sorbara	NULL
L	NULL
,	NULL
Himmelmann	NULL
AW	NULL
,	NULL
Bagdi	NULL
E	NULL
,	NULL
Jaffe	NULL
ES	NULL
,	NULL
Raffeld	NULL
M	NULL
:	NULL
Cytotoxic	NULL
cell	NULL
antigen	NULL
expression	NULL
in	NULL
anaplastic	NULL
large	NULL
cell	NULL
lymphomas	NULL
of	NULL
T-	NULL
and	NULL
null-cell	NULL
type	NULL
and	NULL
Hodgkin	NULL
's	NULL
disease	NULL
:	NULL
Evidence	NULL
for	NULL
distinct	NULL
cellular	NULL
origin	NULL
.	NULL

Blood	NULL
89:980	NULL
,	NULL
1997	NULL
38	NULL
.	NULL

Jacobs	NULL
TW	NULL
,	NULL
Prioleau	NULL
JE	NULL
,	NULL
Stillman	NULL
IE	NULL
,	NULL
Schnitt	NULL
SJ	NULL
:	NULL
Loss	NULL
of	NULL
tumor	NULL
marker-immunostaining	NULL
intensity	NULL
on	NULL
stored	NULL
paraffin	NULL
slides	NULL
of	NULL
breast	NULL
cancer	NULL
.	NULL

J	NULL
Natl	NULL
Cancer	NULL
Inst	NULL
88:1054	NULL
,	NULL
1996	NULL
39	NULL
.	NULL

Dorfler	NULL
P	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
C-terminal	NULL
activating	NULL
and	NULL
inhibitory	NULL
domains	NULL
determine	NULL
the	NULL
transactivation	NULL
potential	NULL
of	NULL
BSAP	NULL
(	NULL
Pax-5	NULL
)	NULL
,	NULL
Pax-2	NULL
and	NULL
Pax-8	NULL
.	NULL

EMBO	NULL
J	NULL
15:1971	NULL
,	NULL
1996	NULL
40	NULL
.	NULL

Hodgkin	NULL
PD	NULL
,	NULL
Lee	NULL
J-H	NULL
,	NULL
Lyons	NULL
AB	NULL
:	NULL
B	NULL
cell	NULL
differentiation	NULL
and	NULL
isotype	NULL
switching	NULL
is	NULL
related	NULL
to	NULL
division	NULL
cycle	NULL
number	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
184:277	NULL
,	NULL
1996	NULL
41	NULL
.	NULL

Martinez-Valdez	NULL
H	NULL
,	NULL
Malisan	NULL
F	NULL
,	NULL
de	NULL
Bouteillet	NULL
O	NULL
,	NULL
Guret	NULL
C	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Liu	NULL
YJ	NULL
:	NULL
Molecular	NULL
evidence	NULL
that	NULL
isotype	NULL
switching	NULL
occurs	NULL
within	NULL
the	NULL
germinal	NULL
centers	NULL
.	NULL

Ann	NULL
NY	NULL
Acad	NULL
Sci	NULL
764:151	NULL
,	NULL
1995	NULL
42	NULL
.	NULL

Schmid	NULL
C	NULL
,	NULL
Isaacson	NULL
PG	NULL
:	NULL
Proliferation	NULL
centres	NULL
in	NULL
B-cell	NULL
malignant	NULL
lymphoma	NULL
,	NULL
lymphocytic	NULL
(	NULL
B-CLL	NULL
)	NULL
:	NULL
An	NULL
immunophenotypic	NULL
study	NULL
.	NULL

Histopathology	NULL
24:445	NULL
,	NULL
1994	NULL
43	NULL
.	NULL

Malisan	NULL
F	NULL
,	NULL
Fluckiger	NULL
A-C	NULL
,	NULL
Ho	NULL
S	NULL
,	NULL
Guret	NULL
C	NULL
,	NULL
Banchereau	NULL
J	NULL
,	NULL
Martinez-Valdez	NULL
H	NULL
:	NULL
B-chronic	NULL
lymphocytic	NULL
leukemias	NULL
can	NULL
undergo	NULL
isotype	NULL
switching	NULL
in	NULL
vivo	NULL
and	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
differentiate	NULL
and	NULL
switch	NULL
in	NULL
vitro	NULL
.	NULL

Blood	NULL
87:717	NULL
,	NULL
1996	NULL
44	NULL
.	NULL

Dunn-Walters	NULL
DK	NULL
,	NULL
Isaacson	NULL
PG	NULL
,	NULL
Spencer	NULL
J	NULL
:	NULL
Analysis	NULL
of	NULL
mutations	NULL
in	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
variable	NULL
region	NULL
genes	NULL
of	NULL
microdissected	NULL
marginal	NULL
zone	NULL
(	NULL
MGZ	NULL
)	NULL
B	NULL
cells	NULL
suggests	NULL
that	NULL
the	NULL
MGZ	NULL
of	NULL
human	NULL
spleen	NULL
is	NULL
a	NULL
reservoir	NULL
of	NULL
memory	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
182:559	NULL
,	NULL
1995	NULL
45	NULL
.	NULL

Dunn-Walters	NULL
DK	NULL
,	NULL
Isaacson	NULL
PG	NULL
,	NULL
Spencer	NULL
J	NULL
:	NULL
Sequence	NULL
analysis	NULL
of	NULL
KRENACS	NULL
ET	NULL
AL	NULL
rearranged	NULL
IgVy	NULL
genes	NULL
from	NULL
microdissected	NULL
human	NULL
Peyer	NULL
's	NULL
patch	NULL
marginal	NULL
zone	NULL
B	NULL
cells	NULL
.	NULL

Immunology	NULL
88:618	NULL
,	NULL
1996	NULL
46	NULL
.	NULL

Kuppers	NULL
R	NULL
,	NULL
Hajadi	NULL
M	NULL
,	NULL
Plank	NULL
L	NULL
,	NULL
Rajewsky	NULL
K	NULL
,	NULL
Hansmann	NULL
ML	NULL
:	NULL
Molecular	NULL
Ig	NULL
gene	NULL
analysis	NULL
reveals	NULL
that	NULL
monocytoid	NULL
B	NULL
cell	NULL
lymphoma	NULL
is	NULL
a	NULL
malignancy	NULL
of	NULL
mature	NULL
B	NULL
cells	NULL
carrying	NULL
somatically	NULL
mutated	NULL
V	NULL
region	NULL
genes	NULL
and	NULL
suggests	NULL
that	NULL
rearrangement	NULL
of	NULL
the	NULL
kappa-deleting	NULL
element	NULL
(	NULL
resulting	NULL
in	NULL
deletion	NULL
of	NULL
the	NULL
Ig	NULL
kappa	NULL
enhancers	NULL
)	NULL
abolishes	NULL
somatic	NULL
hypermutation	NULL
in	NULL
the	NULL
human	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
26:1794	NULL
,	NULL
1996	NULL
47	NULL
.	NULL

Mahmoud	NULL
MS	NULL
,	NULL
Huang	NULL
N	NULL
,	NULL
Nobuyoshi	NULL
M	NULL
,	NULL
Lisukov	NULL
IA	NULL
,	NULL
Tanaka	NULL
H	NULL
,	NULL
Kawano	NULL
MM	NULL
:	NULL
Altered	NULL
expression	NULL
of	NULL
Pax-5	NULL
gene	NULL
in	NULL
human	NULL
myeloma	NULL
cells	NULL
.	NULL

Blood	NULL
87:4311	NULL
,	NULL
1996	NULL
48	NULL
.	NULL

Davis	NULL
RE	NULL
,	NULL
Dorfman	NULL
RF	NULL
,	NULL
Warnke	NULL
RA	NULL
:	NULL
Primary	NULL
large-cell	NULL
lymphoma	NULL
of	NULL
the	NULL
thymus	NULL
:	NULL
A	NULL
diffuse	NULL
B-cell	NULL
neoplasm	NULL
presenting	NULL
as	NULL
primary	NULL
mediastinal	NULL
lymphoma	NULL
.	NULL

Hum	NULL
Pathol	NULL
21:1262	NULL
,	NULL
1990	NULL
49	NULL
.	NULL

Kanavaros	NULL
P	NULL
,	NULL
Gaulard	NULL
P	NULL
,	NULL
Charlotte	NULL
F	NULL
,	NULL
Martin	NULL
N	NULL
,	NULL
Ducos	NULL
C	NULL
,	NULL
Lebezu	NULL
M	NULL
,	NULL
Mason	NULL
DY	NULL
:	NULL
Discordant	NULL
expression	NULL
of	NULL
immunoglobulin	NULL
and	NULL
its	NULL
associated	NULL
molecule	NULL
mb-1/CD79a	NULL
is	NULL
frequently	NULL
found	NULL
in	NULL
mediastinal	NULL
large	NULL
B	NULL
cell	NULL
lymphomas	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
146:735	NULL
,	NULL
1995	NULL
50	NULL
.	NULL

Hsu	NULL
S-M	NULL
,	NULL
Hsu	NULL
P-L	NULL
:	NULL
The	NULL
nature	NULL
of	NULL
Reed-Sternberg	NULL
cells	NULL
:	NULL
Phenotype	NULL
,	NULL
genotype	NULL
,	NULL
and	NULL
other	NULL
properties	NULL
.	NULL

Crit	NULL
Rev	NULL
Oncogene	NULL
5:213	NULL
,	NULL
1994	NULL
51	NULL
.	NULL

Tamaru	NULL
J	NULL
,	NULL
Hummel	NULL
M	NULL
,	NULL
Zemlin	NULL
M	NULL
,	NULL
Kalvelage	NULL
B	NULL
,	NULL
Stein	NULL
H	NULL
:	NULL
Hodgkin	NULL
's	NULL
disease	NULL
with	NULL
a	NULL
B-cell	NULL
phenotype	NULL
often	NULL
shows	NULL
a	NULL
VDJ	NULL
rearrangement	NULL
and	NULL
somatic	NULL
mutations	NULL
in	NULL
the	NULL
VH	NULL
genes	NULL
.	NULL

Blood	NULL
84:708	NULL
,	NULL
1994	NULL
52	NULL
.	NULL

Orazi	NULL
A	NULL
,	NULL
Jiang	NULL
B	NULL
,	NULL
Lee	NULL
CH	NULL
,	NULL
English	NULL
GW	NULL
,	NULL
Cattoretti	NULL
G	NULL
,	NULL
John	NULL
K	NULL
,	NULL
Neiman	NULL
RS	NULL
:	NULL
Correlation	NULL
between	NULL
presence	NULL
of	NULL
clonal	NULL
rearrangements	NULL
of	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
genes	NULL
and	NULL
B-cell	NULL
antigen	NULL
expression	NULL
in	NULL
Hodgkin	NULL
's	NULL
disease	NULL
.	NULL

Am	NULL
J	NULL
Clin	NULL
Pathol	NULL
104:413	NULL
,	NULL
1995	NULL
53	NULL
.	NULL

Offit	NULL
K	NULL
,	NULL
Parsa	NULL
N	NULL
,	NULL
Filippa	NULL
D	NULL
,	NULL
Jhanwar	NULL
S	NULL
,	NULL
Chaganti	NULL
RSK	NULL
:	NULL
t	NULL
(	NULL
9	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
;	NULL
q32	NULL
)	NULL
denotes	NULL
a	NULL
subset	NULL
of	NULL
low	NULL
grade	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
with	NULL
plasmacytoid	NULL
differentiation	NULL
.	NULL

Blood	NULL
80:2594	NULL
,	NULL
1992	NULL
54	NULL
.	NULL

Busslinger	NULL
M	NULL
,	NULL
Klix	NULL
N	NULL
,	NULL
Pfeffer	NULL
P	NULL
,	NULL
Graninger	NULL
PG	NULL
,	NULL
Kozmik	NULL
Z	NULL
:	NULL
Deregulation	NULL
of	NULL
PAX-5	NULL
by	NULL
translocation	NULL
of	NULL
the	NULL
Ep	NULL
enhancer	NULL
of	NULL
the	NULL
IgH	NULL
locus	NULL
adjacent	NULL
to	NULL
two	NULL
alternative	NULL
PAX-5	NULL
promoters	NULL
in	NULL
a	NULL
diffuse	NULL
large-cell	NULL
lynphoma	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:6129	NULL
,	NULL
1996	NULL
55	NULL
.	NULL

Pilz	NULL
A	NULL
,	NULL
Fountain	NULL
J	NULL
,	NULL
Peters	NULL
J	NULL
,	NULL
Abbott	NULL
C	NULL
:	NULL
Linkage	NULL
mapping	NULL
of	NULL
the	NULL
Aldo-2	NULL
,	NULL
Pax-5	NULL
,	NULL
Ambp	NULL
,	NULL
and	NULL
D4h9S3E	NULL
loci	NULL
on	NULL
mouse	NULL
chromosome	NULL
4	NULL
in	NULL
the	NULL
region	NULL
of	NULL
homology	NULL
with	NULL
human	NULL
chromosome	NULL
9	NULL
.	NULL

Genomics	NULL
18:705	NULL
,	NULL
1993	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blOOd	NULL
1998	NULL
92	NULL
:	NULL
1308-1316	NULL
Transcription	NULL
Factor	NULL
B-Cell-Specific	NULL
Activator	NULL
Protein	NULL
(	NULL
BSAP	NULL
)	NULL
Is	NULL
Differentially	NULL
Expressed	NULL
in	NULL
B	NULL
Cells	NULL
and	NULL
in	NULL
Subsets	NULL
of	NULL
B-Cell	NULL
Lymphomas	NULL
Laszlo	NULL
Krenacs	NULL
,	NULL
Andreas	NULL
W.	NULL
Himmelmann	NULL
,	NULL
Leticia	NULL
Quintanilla-Martinez	NULL
,	NULL
Thierry	NULL
Fest	NULL
,	NULL
Agostino	NULL
Riva	NULL
,	NULL
Axel	NULL
Wellmann	NULL
,	NULL
Eniko	NULL
Bagdi	NULL
,	NULL
John	NULL
H.	NULL
Kehrl	NULL
,	NULL
Elaine	NULL
S.	NULL
Jaffe	NULL
and	NULL
Mark	NULL
Raffeld	NULL
4	NULL
VIN	NULL
“	NULL
CA	NULL
VJ-	NULL
,	NULL
'	NULL
\se	NULL
@	NULL
.	NULL

2	NULL
YOtow®	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/92/4/1308.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5679	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

